JP2010090151A - Bipolar trans carotenoid salt and its use - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a bipolar trans carotenoid salt compound useful for improving diffusion of oxygen between a red blood cell and a body tissue in a mammal including a human, and to provide the pharmaceutical application. <P>SOLUTION: The compound is expressed by formula YZ-TCRO-ZY (for example, formula (1)) and is not trans sodium crocetinate. In the formula, Y is a cation, Z is a polar group combined with the cation, and TCRO is a trans carotenoid skeleton. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to bipolar trans carotenoid salt compounds, methods for solubilizing them, methods for making them, and methods for using them. These bipolar trans carotenoid salt (BTCS) compounds are useful for improving oxygen diffusivity between red blood cells and body tissues in mammals, including humans.

  Carotenoids are a type of hydrocarbon composed of isoprenoid units linked so that their arrangement is reversed at the center of the molecule. The skeleton of this molecule consists of conjugated carbon-carbon double bonds and single bonds, optionally also with pendant groups. In the past, carotenoid skeletons were thought to contain 40 carbons, but it has long been recognized that some carotenoids have carbon skeletons with less than 40 carbon atoms. All four single bonds around the carbon-carbon double bond are located in the same plane. If pendant groups are on the same side of the carbon-carbon double bond, they are referred to as cis. If pendant groups are on the opposite side of the carbon-carbon bond, they are called trans. Numerous double bonds have enormous potential for carotenoid geometric (cis / trans) isomerism, and isomerization occurs easily in solution. A recent series of books is an excellent reference on many of the properties of carotenoids etc. (see “Carotenoids”, G. Britton, S. Liaaen-Jensen and H. Pfander, Birkhauser Verlag, Basel, 1995). Are incorporated herein in their entirety).

  Many carotenoids are nonpolar and are therefore insoluble in water. These compounds are extremely hydrophobic and therefore require the use of organic rather than aqueous solvents to solubilize them, making them difficult to formulate for biological use. ing. Some carotenoids are monopolar and have surfactant properties (hydrophobic moieties and hydrophilic polar groups). These compounds are attracted to the surface of the aqueous solution rather than dissolved in the bulk liquid. There are a small number of natural bipolar carotenoid compounds that contain a central hydrophobic moiety and two polar groups, one at each end of the molecule. Carotenoid sulfate has been reported to have “great solubility up to 0.4 mg / mL” in water (“Carotenoids” 1A, 283 pages). Some carotenoids that are considered bipolar are not very soluble in water. For example, dialdehyde and diketone. Although the dipyridine salt of crocetin has been reported, its solubility in water is less than 1 mg / mL at room temperature. Other bipolar carotenoids include crocetin and crocin (both found in the spice saffron). However, crocetin is only slightly soluble in water. In fact, of all bipolar carotenoids, only crocin shows significant solubility in water.

  U.S. Pat. Nos. 4,176,179, 4,070,460, 4,048,880, 4,038,144, 4,0092,970, 3,975,519, 3,965,261, 3,853,933 and 3,788,468 relate to various uses of crocetin.

  U.S. Pat. No. 5,107,030 relates to a process for producing 2,7-dimethyl-2,4,6-octatrienedial and derivatives thereof.

  U.S. Pat. No. 6,060,511 relates to trans sodium crocetinate (TSC) and uses thereof. TSC is produced by reacting natural saffron with sodium hydroxide followed by extraction.

  In Roy et al., Shock 10, pp. 213-7 (1998), hemorrhagic rats (55% of the blood volume) were given a bolus of transsodium crocetinate (TSC) after the end of the hemorrhage, followed by a further 30 minutes of saline. Water was given. All animals treated with TSC survived, but all control animals died. In the TSC group, systemic oxygen consumption increased, reaching 75% of normal rest after about 15 minutes.

  Laidig et al., J Am Chem. Soc. 120, 9394-9395 (1998) relates to computer modeling of TSC. The simulated TSC molecules were “hydrated” by surrounding them with water molecules. Rearranging the water around the TSC made it easier for oxygen molecules to diffuse into the system. The calculated diffusivity increased by about 30%, which was consistent with the results obtained in both in vitro and animal experiments.

  In Singer et al., Crit Care Med 28, 1968-72 (2000), TSC improved hemodynamics and prolonged rat survival in a rat model of acute hypoxia. Hypoxia was induced using a hypoxic (10%) air mixture and 10 minutes later animals were given saline or TSC. Hypoxia has resulted in decreased blood flow and increased base deficiency. In the control group, only 2 out of 6 animals survived. In the treatment group, everything was alive and hemodynamics showed sufficient stability for more than 2 hours and then slowly worsened.

The present invention has the following structure:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Bipolar trans carotenoid salt (BTCS) compounds having the formula and the synthesis of such compounds.

  The present invention also has a value obtained by dividing the absorbance of the maximum peak (in the aqueous solution of the BTCS composition) occurring in the visible light wavelength region by the absorbance of the peak occurring in the UV wavelength region is more than 7.0, preferably 7.5. And most preferably more than 8 compositions of individual BTCS compounds (including TSC compositions).

The present invention also provides the following formula:
YZ-TCRO-ZY
It relates to a method for treating various diseases comprising administering to a mammal in need of treatment a therapeutically effective amount of a compound having

The present invention also provides the following formula:
YZ-TCRO-ZY
Several methods of solubilizing and synthesizing compounds having a

  The invention also relates to an inhaler for delivering a compound of the invention.

  A new class of carotenoids and carotenoid related compounds has been found. These compounds are referred to as “bipolar trans carotenoid salts” (BTCS).

(Compound of the present invention)
The present invention relates to bipolar trans carotenoid salts that are a group of compounds that allow hydrophobic carotenoids or carotenoid-related skeletons to dissolve in aqueous solutions, and methods for their production. The cations of these salts include many species, but sodium or potassium (these are found in most biological systems) are preferred. U.S. Pat. No. 6,060,511 held by the inventors of this application (incorporated herein by reference in its entirety) extracts transsodium crocetinate (TSC) (one of BTCS) from saffron. A method is described.

The general structure of a bipolar trans carotenoid salt is represented by the following formula.
YZ-TCRO-ZY

In the formula, Y (which may be the same or different at both ends) is a cation, preferably Na ⁺ , K ⁺ or Li ⁺ . Y is preferably a monovalent metal ion. Y is an organic cation, for example, R ₄ N ⁺ , R ₃ S ⁺ [R is H, or C _n H _{2n + 1} (n is 1 to 10, preferably 1 to 6). R is, for example, methyl, ethyl, propyl or butyl. ] May be used.

In the formula, Z (which may be the same or different at both ends) is a polar group bonded to the cation. Such groups optionally include a terminal carbon on the carotenoid (or carotenoid related compound), for example, a carboxyl (COO ⁻ ) group or a CO group. Further, it may be a sulfate group (OSO ₃ ⁻ ), a monophosphate group (OPO ₃ ⁻ ), (OP (OH) O ₂ ⁻ ), a diphosphate group, triphosphoric acid, or a combination thereof.

  TCRO is a trans carotenoid or carotenoid related skeleton (preferably less than 100 carbons) that is linear and has a pendant group (defined below), generally “conjugated”, ie alternating It includes linked carbon-carbon double bonds and single bonds (in one embodiment, TCRO is not fully conjugated like lycopene). The pendant group is generally a methyl group, but may be other groups as described below. In a preferred embodiment, the backbone units are linked so that their arrangement is reversed at the center of the molecule. All four single bonds around the carbon-carbon double bond are located in the same plane. If pendant groups are on the same side of the carbon-carbon double bond, they are referred to as cis. If present on the opposite side of the carbon-carbon bond, it is referred to as trans. The compound of the present invention is trans. The cis isomer is generally detrimental and does not increase diffusivity. In one embodiment, trans isomers can be utilized where the backbone remains linear.

The trans carotenoid or carotenoid-related skeleton is represented by the following formula, for example.

In the formula, the pendant group X (which may be the same or different) is a hydrogen (H) atom or a linear or branched group (halogen) having 10 or less, preferably 4 or less carbon atoms. Optionally), or halogen. X is, for example, a methyl group (CH ₃ ), an ethyl group (C ₂ H ₅ ), a halogen-containing alkyl group (C _{1 to} C ₁₀ ) (for example, CH ₂ Cl), or a halogen (for example, Cl or Br). The pendant groups X may be the same or different, but it is necessary to use a group that maintains the skeleton in a straight chain as the X group.

  Although many carotenoids exist in nature, carotenoid salts do not exist in nature. US Pat. No. 6,060,511, owned by the inventor of the present application, relates to transsodium crocetinate (TSC). TSC was produced by reacting natural saffron with sodium hydroxide followed by an extraction that primarily selects the trans isomer.

  The presence of the cis and trans isomers of BTCS can be determined by examining the UV-visible spectrum of a carotenoid sample dissolved in an aqueous solution. If a spectrum is obtained, the value obtained by dividing the absorbance value of the maximum peak occurring in the visible light wavelength region of 416 to 423 nm (the number is determined according to the solvent used) by the absorbance of the peak occurring in the UV wavelength region of 250 to 256 nm. Can be used to determine the purity level of the trans isomer. When BTCS is dissolved in water, the maximum peak in the visible light wavelength region is at about 421 nm and the peak in the UV wavelength region is at about 254 nm. M.M. Craw and C.I. According to Lambert, Photochemistry and Photobiology, Vol. 38 (2), pages 241-243 (1983) (which is incorporated herein by reference in its entirety), the calculation results (when analyzing crocetin) are 3. 1 and its value increased to 6.6 after purification.

  U.S. Pat. No. 6,060,511 trans sodium crocetin (TSC produced by reacting natural saffron with sodium hydroxide and then extracting primarily to select the trans isomer) owned by the inventor of the present application. And Craw and Lambert analysis using cuvettes designed for the visible light wavelength region, an average value of about 6.8 is obtained. When this test is performed on a synthetic TSC of the present invention, the ratio is greater than 7.0 (eg, 7.0-8.5), preferably greater than 7.5 (eg, 7.5-8. 5) Most preferably, the value exceeds 8. For TSC synthesized by a modified method of Example 5, the ratio exceeds 7.4 (eg, 7.4 to 8.5). The synthesized material is a “purer”, ie highly purified trans isomer.

  Recently, TSC has been found to have a water solubility of about 10 mg / mL at room temperature, but that value is unusual for a molecule containing such a long hydrophobic moiety. TSC has also been found to increase the diffusivity of oxygen in liquids.

  US Pat. No. 6,060,511 describes an extraction method for producing TSC from saffron, but using saffron, only a single carotenoid skeleton can be incorporated into the salt, Bipolar carotenoids cannot be produced.

  The invention disclosed herein allows the synthesis of a group of compounds, ie all bipolar trans carotenoid salts containing various carotenoids or carotenoid related skeletons. Such compounds are soluble in aqueous solutions and have advantageous biological uses and can be used, for example, to increase oxygen utilization. This increase is thought to be because the hydrophobic part (skeleton) of the bipolar trans carotenoid salt can influence the binding of water molecules. In fact, this allows oxygen molecules to diffuse more rapidly in that region.

(Solubilization of compounds and compositions of the present invention)
According to the present invention, trans carotenoids or carotenoid related skeleton molecules can be dissolved in an aqueous solution. Hereinafter, a novel dissolution method will be described. The method applies to any bipolar trans carotenoid salt and composition thereof.

BTCS-containing saline for injection:
For the treatment of hemorrhagic shock, a large volume (three times the estimated blood loss) of isotonic saline (also called saline) is infused. Isotonic saline contains 9 g of NaCl per liter of water so as not to disturb the ionic strength of the plasma when injected into the body. It has been found that adding TSC to this saline solution provides an excellent infusion solution, but such a solution cannot be prepared by simply mixing TSC powder and its saline solution. No matter how much TSC is added (up to a few milligrams per mL), about 50% of the TSC dissolves in saline. This means that insoluble TSC particles are still present. To prevent this, a stock solution may be prepared by adding more than twice the required amount of TSC and then removing undissolved particles by centrifugation. The actual composition of the stock solution can be confirmed using UV-visible spectroscopy. This stock solution can be added to saline, but the TSC remains dissolved.

This method can be used to dissolve BTCS in other types of sodium chloride solutions and solutions of salts (KCl, Na ₂ SO ₄ , lactate, etc.). Thus, several mg / mL (for example, 1-3 mg / mL) can be made into a solution.

A dilute solution of sodium carbonate dissolves BTCS:
BTCS, such as TSC, dissolves in extremely dilute sodium carbonate solution. A dilute solution of sodium carbonate (eg, a 0.00001-0.001M solution) can be added dropwise to deionized water until the pH of deionized water (usually 5-6) is 8.0. This requires only a few drops of extremely dilute sodium carbonate per 50 mL of deionized water, for example. This sodium carbonate-deionized aqueous solution can completely dissolve a large amount of TSC (about 10 mg / mL). This is a surprising amount considering the hydrophobicity of the carotenoid portion of BTCS.

  BTCS can be supplied as a powder with a sterile bottle containing sodium carbonate water. This high-concentration solution can be injected directly (only a small amount of a solution having a lower ionic strength than plasma can be injected), and the high-concentration solution can be injected after being added to physiological saline. Can do. If TSC is dissolved in a sodium carbonate-water solvent, even if a larger amount of the same solvent is added thereafter, TSC remains in a solution state.

  In another embodiment, sodium bicarbonate is used in place of sodium carbonate. Other salts that produce deionized water having a basic pH can also be used.

  A carotenoid skeleton concentration of 5-10 mg / mL can be achieved with this method.

Water dissolves BTCS:
TSC dissolves in water (tap water, distilled water, deionized water), but these solutions are not stable unless the pH is adjusted to be basic. TSC is more soluble in deionized water (there is a very small amount of Na ⁺ ions) than in standard water. Although BTCS including TSC dissolves in deionized water alone, TSC precipitates when unadjusted deionized water is added to the solution. BTCS dissolves in deionized water alone, but if the pH is not adjusted to be slightly basic, the addition of deionized water causes precipitation of BTCS.

Other methods of solubilizing BTCS:
BTCS can be formulated into a delivery system that enhances drug delivery. See Formulation of Compounds of the Invention (described below).

(Synthesis method of bipolar trans carotenoid salt which is the compound of the present invention)
Hereinafter, a novel synthesis method that can be used for the synthesis of a bipolar trans carotenoid salt will be described. In some cases, various synthetic steps have variations that will be apparent to those skilled in the art.

A. Synthesis method of TSC:
Trans Soddy crocetinate (TSC) is conjugated carbon - symmetrical _{C 10} dialdehyde which contains carbon-to-carbon double bonds (2,7-dimethyl-octa-2,4,6-triene-1,8-dial) [3- It can be synthesized by coupling with carbomethoxy-2-butene-1-ylidene] triphenylphosphorane. This forms a trans dimethyl ester of crocetin. This dimethyl ester is then converted to the final product TSC by saponification. In general, saponification is carried out by treating the ester with either an aqueous sodium hydroxide solution or a sodium hydroxide solution in THF (tetrahydrofuran), but these methods have not yielded the best results. In this case, saponification can be performed very well by reacting the ester with a NaOH / methanol solution. TSC is recovered by vacuum drying after saponification.

C ₁₀ dialdehyde and triphenylphosphorane is a reactant used in this synthesis can be prepared by a variety of routes. For _{example, C 10} dialdehyde, using Wittig (Wittig) reaction, was prepared from ethyl bromoacetate and furan. In the preparation of the desired phospholane, tiglic acid was the starting material. By concatenating various lengths of reactants (eg, C ₁₄ dialdehyde and triphenylphosphorane), various lengths of carotenoid skeletons can be produced. By this method, various trans bipolar carotenoid salts are formed. Modifications can also be made to obtain various pendant groups (TSCs have a methyl group as the pendant group).

  The TSC produced in this way is soluble in water (at pH adjusted to 8.0 with a very dilute solution of sodium carbonate) at a level of> 10 mg / mL at room temperature. There are other bipolar trans carotenoid salts that are soluble at room temperature in water having a pH above neutral. In the present specification, “soluble” means that an amount exceeding 5 mg per mL of water dissolves at room temperature (as described above, in the carotenoid reference, 0.4 mg / mL is “ "Very high solubility", which is lower than the definition of solubility in this specification).

B. General synthetic method:
Carotenoids or carotenoid-related structures can be constructed as follows.

  (3-Carbomethoxy-2-buten-1-ylidene) triphenylphosphorane (or related compound when X is other than a methyl group) is an isoprenoid unit (or an isoprenoid-related unit) that is a symmetrical carotenoid (or carotenoid-related compound) ) Is an important precursor to be added at both ends. This process can be repeated indefinitely. For example, dimethyltranscrocetinate can be reduced to the corresponding symmetric dialdehyde using the above chemical reaction. The dialdehyde can be reacted with excess (3-carbomethoxy-2-buten-1-ylidene) triphenylphosphorane to give the corresponding diester. This series of synthesis procedures can be repeated many times.

(Improved synthesis method)
2,7-dimethyl-2,4,6-octatriene dial (2,7-dimethylocta 2,4,6-triene-1,8 dial) is an important intermediate in the TSC synthesis. This important precursor has three double bonds and therefore several isomers are possible. For TSC, all-trans isomers (E, E, E-isomers) are required. The general synthesis route requires 11 steps of synthesis, with some yields being relatively low and poor selectivity (see Example 1). Eventually, on the way, it is necessary to perform column chromatography to purify some intermediates.

  The improved synthetic route is much simpler (see reaction scheme below). According to the three-step process described in US Pat. No. 5,107,030 (incorporated herein by reference in its entirety), a mixture of geometric isomers of dialdehyde is obtained (in US Pat. No. 5,107,030, this mixture). Not mentioned). In the process of the invention described in Example 1, 96-97% of the desired isomer (all-trans or E, E, E-isomer) is obtained by several recrystallizations from methanol or ethyl acetate. % Yield.

The improved synthesis method of the present invention is carried out in a suitable solvent (for example, 1,4-dioxane, tetrahydrofuran, or dialkyl ether [the alkyl group is one or two C1-C10 linear or branched alkyl groups]). And sulfinic acid (RSO ₂ H) such as para-toluenesulfinic acid [wherein R is a C1-C10 linear or branched alkyl group, or an aryl group (substituted phenyl group). ] To convert the remaining isomeric mixture of dialdehydes to the desired transaldehyde (E, E, E). Furthermore, the pure desired dialdehyde is obtained in a yield of 8%, and the overall yield of the final step is increased from 59% to 76%. This improvement in yield is important. A better yield can be obtained if this isomerization step is incorporated into the third step of the method of US Pat. No. 5,107,030.

Improved synthesis route:

Two undesirable isomers:

Isomerization of unwanted dialdehyde to desired dialdehyde:

Saponification can be performed by dissolving the diester in methanol and then adding a base such as NaOH (in the case of NaOH, Y in BTCS is Na ⁺ ). Alternatively, the diester may be dissolved in methanol that already contains a base. NaOH is generally an aqueous solution (20-60 wt%), but may be solid. As a solvent for dissolving the diester, ethanol, propanol and isopropanol may be used instead of methanol. Saponification can be performed commercially in various ways. One-phase or two-phase systems (one organic phase and one aqueous phase) can be used.

  Transcrocetin can also be synthesized by the above method.

  Furthermore, as reported for TSC, such BTCS compounds increase the diffusivity of oxygen in water (the hydrophobic interaction between the carotenoid skeleton and water is believed to result in increased diffusivity. Thus, the increase in diffusivity may also depend on the nature of the hydrophobic moiety incorporated in the final product (eg, carbon chain length).

(Formulation of the compound of the present invention)
A high concentration solution of a bipolar trans carotenoid salt can be prepared by dissolving in an extremely dilute solution of sodium carbonate as described above. The resulting mixture may be used as is or further diluted with saline or other aqueous solvents. A solution of the bipolar trans carotenoid salt can be further prepared by dissolving the bipolar trans carotenoid salt directly in the salt solution and then removing the undissolved material.

  Bipolar trans carotenoid salts are stable in dry form at room temperature and can be stored for long periods of time. Such salt formulations are preferably absorbed in the intestine rather than the stomach when administered orally.

  The compounds of the present invention can be administered alone, but can also be administered as part of a pharmaceutical formulation. Such formulations may include pharmaceutically acceptable carriers and other therapeutic agents known to those skilled in the art (see below). It is preferred that the formulation does not contain a compound that inhibits the ability of the compounds of the invention to improve oxygen diffusivity.

  Appropriate dosages of the compounds and compositions of the invention will depend on the severity of the condition being treated. In order for a dose to be “therapeutically effective” it needs to have the desired effect, ie, increased oxygen diffusivity. Thus, next, the oxygen-related parameter returns to a normal value.

  Administration can be by any suitable route (eg, oral, nasal, topical, parenteral (subcutaneous, intramuscular, intravenous, intradermal, intraosseous, etc.), vaginal or rectal). The preferred route of administration depends on the situation. In emergency situations where BTCS needs to enter the bloodstream very quickly, the inhalation route is advantageous for treatment. Accordingly, formulations also include those suitable for administration by such routes (spraying liquids or powders). It will be appreciated that the preferred route will vary with for example the condition and age of the patient. The preparation can be appropriately provided in a unit dosage form such as a tablet and sustained-release capsule, and can be prepared and administered by a method known in the pharmaceutical field. The formulation may be for immediate release of BTCS, or for sustained or controlled release. See, for example, the sustained release formulation of WO 99/15150 (incorporated herein by reference in its entirety).

  Formulations of the present invention suitable for oral administration are as individual units such as pills, capsules, cachets or tablets, or as powders or granules, or solutions, suspensions or emulsions. Can be offered as. Examples of formulations suitable for oral administration further include lozenges, pills, and inhalation mists administered in a suitable base or liquid carrier. Formulations for topical administration to the skin can be provided as ointments, creams, gels or pastes containing the active agent and a pharmaceutically acceptable carrier, or in the form of a patch.

  Examples of formulations suitable for nasal administration wherein the carrier is a solid include powders of particle size that can be administered by rapid inhalation through the nasal passages. Suitable formulations in which the carrier is a liquid can be administered, for example, as a nasal spray or nasal drop.

  Examples of formulations suitable for parenteral administration include aqueous and non-aqueous sterilizations that may contain antioxidants, buffers, bacteriostatic agents, and solutes that render the formulation isotonic with the blood of the intended recipient. Injection solutions and aqueous and non-aqueous sterile suspensions that may contain suspending and thickening agents are included. The formulation can be provided in the form of unit or multi-dose containers, such as sealed ampoules or sealed vials, and can be lyophilized followed by a sterile liquid carrier such as water for injection. It can be in a state that only needs to be added immediately before use. Injection and suspension injections can be prepared from sterile powders, granules, and tablets.

(Use of compounds and compositions of the invention)
Delivery of oxygen to body tissue controls or mediates a wide variety of conditions. The compounds and compositions of the invention can be used in the same pharmaceutical uses and the same effective amounts as described for crocetin. U.S. Pat. Incorporated herein by reference in its entirety).

  TSC has been shown to increase oxygen diffusivity in aqueous solutions by approximately 30%. TSC prolongs survival after hypoxia in mammals, increases oxygen consumption after hypoxia or physical stress, increases blood pressure after hypoxia, reduces blood acidosis after hypoxia (Ie, reduce blood base deficiency, increase blood pH, and reduce plasma lactate levels) and reduce organ damage (eg, liver, kidney) after hypoxia. Accordingly, the compounds of the present invention are suitable for diseases / conditions of mammals (including humans) characterized by hypoxia (hypoxia), such as respiratory diseases, hemorrhagic shock and cardiovascular diseases, in particular (for example Useful for treating multiple organ failure (due to ARDS sepsis or hemorrhagic shock), chronic renal failure, atherosclerosis, emphysema, asthma, hypertension, brain edema, papilloma, spinal cord injury, stroke. The compounds of the present invention are also useful for treating mammals at risk for the above diseases / conditions. Other bipolar trans carotenoid salts have similar properties. Such compounds can also be used in combination with other methods commonly proposed for increasing oxygen utilization in the body (eg, oxygen therapy and the use of hemoglobin or fluorocarbons).

  In one embodiment of the invention, BTCS is administered to the patient while administering oxygen. Alternatively, hemoglobin or fluorocarbon and BTCS can be given together. In these cases, additive effects are realized.

  For any of these salts, the minimum dose required for treatment is that which increases oxygen diffusivity. Effective dosages of the compounds of the invention will depend on the condition being treated, the severity of the condition, and the stage and nature of each mammalian patient being treated. However, the dosage will vary in a range such that the amount of active compound is from about 0.001 mg / kg to about 500 mg / kg, preferably about 0.01-30 mg / kg body weight. IV administration is preferred, but other injection routes (eg, intramuscular, subcutaneous) or inhalation routes can be used. Oral administration can be used, as can transdermal or intraosseous delivery.

Respiratory disorders:
Bipolar trans carotenoid salts can be used to treat acute and chronic respiratory disorders. These are described as a state in which the arterial oxygen partial pressure has been lowered from a normal value of 90 to 100 mmHg, for example, to a value of 60 to 70 mmHg. Examples of such acute and chronic respiratory disorders include emphysema, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) and asthma.

  TSC increases the value of partial pressure of oxygen when it is low (this is a symptom of emphysema, ARDS and COPD). Increasing blood oxygen tension reduces many of the symptoms of emphysema, ARDS and COPD. Although TSC does not remove the cause of the disease, it reduces the oxidative damage and damage resulting from its underlying cause.

Hemorrhagic shock:
Hemorrhagic shock is characterized by a decrease in oxygen consumption. Bipolar trans carotenoid salts increase the body's oxygen consumption by diffusing more oxygen from red blood cells into tissues. TSC has been shown to increase oxygen consumption in rats with hemorrhagic shock and has also been shown to reduce other symptoms of shock. The compounds of the present invention increase low blood pressure, decrease increased heart rate, and reverse blood acidosis that occurred during shock. The compounds of the present invention also reduce organ injury after hemorrhagic shock.

  The compounds of the invention can be used for hemorrhagic shock by inhalation administration or injection, or by addition to a standard resuscitation solution (Lactate Ringer solution or saline).

Cardiovascular disease:
In Western cultures, the main cause of death is ischemic heart disease. Death occurs either by a gradual decline in the heart's ability to contract or, frequently, suddenly stopped. Sudden cardiac death (SCD) occurs between 60 seconds and 24 hours after the onset of symptoms. These deaths are usually the result of acute coronary occlusion (blockage) or ventricular fibrillation (possibly due to occlusion).

  Myocardial ischemia is seen when oxygen supply to the myocardium is inadequate. When coronary blood flow is extremely low, the heart muscle cannot function and die. That area of muscle is said to be infarcted. The decrease in coronary blood flow is most often caused by atherosclerosis that occurs in the coronary arteries. Ischemia results in impaired mechanical and electrical performance, as well as muscle cell damage, which can cause a lethal arrhythmia called ventricular fibrillation (VF). In ventricular fibrillation, the electrical activity of the ventricles becomes disordered and the electrocardiogram has an irregular rhythm and does not have a discernable pattern. Ventricular fibrillation often occurs with myocardial ischemia and myocardial infarction and almost always causes sudden cardiac death. Bipolar trans carotenoid salts are effective in the treatment of myocardial ischemia. Atherosclerosis, which often occurs prior to myocardial ischemia, and congestive heart failure can also be treated with these salts.

Ischemia:
Bipolar trans carotenoid salts are also effective in treating other forms of ischemia (lack of blood flow to tissues or organs) such as renal ischemia, liver ischemia, spinal cord ischemia and cerebral ischemia (eg, stroke). is there.

Surgery:
Surgery often involves either blood loss or arterial clipping (eg, bypass surgery), which can cause ischemia. Bipolar trans carotenoid salts are useful for pre-operative treatment or for treatment during or after surgery.

high blood pressure:
Hypertension, or high blood pressure, is often associated with cardiovascular disease. The compounds of the present invention can be used to lower blood pressure.

Enhanced performance:
BTCS enhances aerobic metabolism by increasing oxygen consumption levels during walking, running, lifting and the like. Endurance also increases.

Traumatic brain injury:
Hypoxia after traumatic brain injury increases brain damage. BTCS increases oxygen levels in brain tissue after impact injury (localized and diffuse injuries). Examples of impact damage include car / motorcycle accidents and falls. BTCS also increases the amount of oxygen that reaches normal brain tissue when hyperoxia is used.

Alzheimer's disease:
BTCS increases brain oxygen consumption levels in Alzheimer's disease and therefore alleviates symptoms of Alzheimer's disease. Blood flow and oxygen consumption are reduced to levels that are about 30% lower than those found in older adults without dementia (Wurtman, Scientific American, Vol. 252, 1985).

  Increased brain oxygen consumption levels with BTCS also reduce memory loss.

Diabetes mellitus:
BTCS is useful for the treatment of diabetic complications (ulcers, gangrene, diabetic retinopathy, etc.). Diabetic foot ulcers are better cured using hyperbaric oxygen breathing therapy (M. Kalani et al., Journal of Diabetes & Its Complications, Vol. 16, No. 2, pages 153-158, 2002).

  BTCS also cures the complication of diabetic retinopathy associated with hypoxic partial pressure (Denningoff et al., Diabetes Technology & Therapeutics, Vol. 2, No. 1, 111-113, 2000).

Other uses:
Bipolar trans carotenoid salts can also be used to treat spinal cord injury, brain edema, anemia and cutaneous papilloma. In either case, the condition is alleviated and the severity is reduced. This is believed to be due to increased oxygen consumption due to the use of bipolar trans carotenoid salts.

Bipolar trans carotenoid salts can also be used to increase the diffusivity of other physiologically important molecules (eg, glucose, CO ₂ or NO). BTCS also removes oxygen-derived free radicals.

  The following examples are illustrative and do not limit the compositions and methods of the present invention. Appropriate changes and adjustments of the various conditions and parameters normally made will be apparent to those skilled in the art and are within the spirit and scope of the invention.

(Example 1: Synthesis of transsodium crocetinate)

Conjugated carbon - by [3-carbomethoxy-2-buten-1-ylidene] triphenylphosphorane coupling a symmetrical C ₁₀ dialdehyde which contains carbon-to-carbon double bond, to synthesize the trans Soddy crocetinate. The product is then saponified using a NaOH / methanol solution.

Triphenylphosphine dissolved in ethyl acetate (at a concentration of about 2 mol / liter) is slowly added to ethyl bromoacetate. After isolation and treatment with base, the product can be treated sequentially with methyl iodide and caustic to form the phosphorane. In this case, the basic compound for forming the carotenoid skeleton can be produced from a cyclic compound such as furan. Furan is reacted with bromine and methanol and undergoes a selective deprotonation step to form the monoaldehyde. This is then coupled with phospholane. The other dimethylacetal group was deprotected under acidic conditions to form the free aldehyde. This compound is then reacted once more with the same phosphorane to give the diethyl diester. The ester group is reduced to an alcohol and further oxidized (eg, using MnO ₂ ) to form a dialdehyde type C ₁₀ skeleton. This is then reacted with a phospholane produced from tiglic acid. The tiglic acid is esterified with methanol under acidic conditions to give the methyl ester, followed by a bromination step. As a result, allyl bromide isomers are formed, which can be separated using crystallization. The desired bromide is then treated with sodium hydroxide to give the desired phosphorane. In addition, the phosphorane and C ₁₀ dialdehyde is dissolved in a solvent such as toluene or benzene and refluxed. The resulting product is isolated as a powder and then saponified with a 40% NaOH / methanol mixture to form a TSC after removal of the solvent.

  Trans-sodium crocetinate 1 (TSC) was prepared in a 17-step synthesis procedure with an overall yield of 1.5%. A total amount of 4.1 g TSC was prepared using ethyl bromoacetate, furan and tiglic acid as starting materials.

Trans-sodium crocetinate (TSC) was synthesized from saponification of dimethyl crocetinate. The preparation of dimethyl crocetinate was based on the total synthesis reported by Buchta and Andrew ¹ . Synthetic strategy for preparing dimethyl crocetinate is symmetrical _{C 10} dialdehyde (2,7-dimethyl-octa-2,4,6-triene-1,8-dial) (3-carbomethoxy-2-butene -Iridene) based on coupling with triphenylphosphorane.

The original Buchta and Andrew paper ¹ was titled “Total Synthesis of trans-2,2-bisdimethyl-crocetin-dimethyl ester and trans-crocetin-dimethyl ester”, but the experimental details and yield Was not reported. Procedure for the various steps leading to C ₁₀ dialdehyde and phosphorane were found after extensive research literature. Eventually, TSC was prepared in 1.5% overall yield in a 17-step procedure using ethyl bromoacetate, furan and tiglic acid as starting materials.

A C ₁₀ symmetrical dialdehyde was prepared from ethyl bromoacetate ² and furan ³ using the Wittig reaction. Treatment of ethyl bromoacetate with triphenylphosphine and methyl iodide gave phosphorane 6.

  The yield of the first step was quite high, 92%. The quantification of subsequent steps in this series of procedures was complicated by the nature of phospholane 4 and phosphonium salt 5. All of these compounds were extremely viscous syrups and actively foamed during concentration on a rotary evaporator. Both compounds could conveniently be handled as a methylene chloride solution and the overall yield of phospholane 6 was considered acceptable from a qualitative point of view (estimated to be higher than 75%).

The furan was ring-opened with bromine to form fumaraldehyde bis (dimethylacetal) 8 ³ .

Mono Deprotection ⁴ under acidic conditions bis (dimethylacetal) 8, to give the aldehyde 9, then it was allowed to phosphorane 6 coupled to give 10 in 45% yield. Acid conditions were used for deprotection of dimethyl acetal 10. Treatment of 11 with phosphorane 6 gave the diester 12. The ester group was reduced to alcohol with DIBAL-H and further oxidized with MnO ₂ to give C ₁₀ dialdehyde 14. From the NMR data, the stereochemical property of 14 was judged to be trans. In particular, the C ₂ symmetry of this compound gives the expected five resonances to the ¹³ C NMR spectrum, and the ¹ H NMR spectrum shows δ9.54 (1H), 7.07 (2H) and 1.95 ( 3H) showed a signal.

  The range of yields for steps h to k reflects the improved isolation from the first pilot experiment to the scaled up reaction.

In a four step procedure, tiglic acid 15 was converted to phospholane 20. The methyl ester 16 was obtained by applying the Fischer esterification conditions to 15. A mixture of 59% methyl γ-bromotiglate and 26% methyl α-bromotiglate was obtained from the reaction using NBS, but the remaining material was unreacted starting material. Based on reported literature, formation of regioisomers was expected ⁵ . In the next step, by recrystallization alpha / gamma mixture phosphonium salt, to give the desired γ- phosphonium bromide 19 ^6. Further treatment with sodium hydroxide gave phosphorane 20.

The phosphorane 20 and _{C 10} dialdehyde 14 were coupled by refluxing in benzene ^6. Dimethyl crocetinate 21 was isolated as a red powder. Methyl ester saponification proved more difficult than expected. Treatment of ester 21 with 2 equivalents of NaOH in THF / H ₂ O at room temperature and refluxing did not change the material. Since solubility was considered a significant problem, pyridine was added. This operation dissolved most of the solid, but no product was obtained upon refluxing a mixture of pyridine and 2.5N NaOH. Standard THF / 2.5N NaOH saponification conditions also did not affect this ester. Eventually, it was found that refluxing 40% NaOH / methanol overnight gave good results. This gave TSC1 as an orange solid.

Attempts were made to dissolve TSC in order to obtain ¹ H NMR spectra. However, TSC was practically insoluble in most common organic solvents (chloroform, DMSO, pyridine, methanol, acetone and glacial acetic acid). The TSC generated from this project was identified by IR, UV, HPLC and elemental analysis. IR showed characteristic absorbance at 1544 and 1402 cm ⁻¹ (in agreement with conjugated carboxylate). UV and HPLC were consistent with the reference TSC ^7. Satisfactory values were obtained from elemental analysis.

  The overall yield for the series of reactions was 1.5% (based on furan).

  Hereinafter, the synthesis will be described in detail.

  All reagents and chemicals were purchased from Aldrich or Sigma and used as received unless otherwise noted. Solvents were purchased from Fisher Scientific as ACS reagents or HPLC grade and used without further purification. Anhydrous solvents were purchased from Aldrich in Sure / Seal ™ bottles and used directly without further purification. Deionized water was obtained from an in-house Culligan water treatment system.

  Melting points were obtained with Mel-Temp II and were not corrected. Infrared spectra were measured with a Perkin-Elmer 1600 FTIR spectrophotometer. Nuclear magnetic spectra were measured with a JEOL FX90Q spectrometer using a 5mm multinuclear probe with internal or external deuterium lock depending on the nature of the sample. Proton and carbon NMR chemical shifts were associated with TMS or deuterium solvents, respectively. Using a coaxial insertion tube of 5% phosphoric acid aqueous solution, a phosphorus NMR spectrum was measured in the proton decoupling mode as usual, and this was used as an external standard.

  Routine analysis by gas chromatography to assess the progress of the reaction and to estimate product composition was performed on a Varian 3700 gas chromatograph equipped with a flame ionization detector and a Hewlett Packard 3394A integrator. Pour 1 microliter of solution into a 15 meter DB5 column (inner diameter 0.53 mm, film thickness 1.5 microns) with helium carrier gas, change from 50 ° C. to 250 ° C. at 20 ° C./min, A temperature program of maintaining for a minute was used. The injector and detector temperature was set at 250 ° C. as usual.

  Depending on the detection method, thin layer chromatography was performed on Baker-flex 2.5 × 7.5 cm silica gel plates with or without the use of fluorescent indicators (1B2 or 1B2-F). Components on the developed plate were detected by UV.

  Elemental analysis is performed by Quantitative Technologies, Inc. (White House, New Jersey).

[(Ethoxycarbonyl) methylene] triphenylphosphorane (4) ² (ACL-G29-1):
Triphenylphosphine (235.6 g, 0.90 mol) was dissolved in EtOAc (540 mL). It took about 30 minutes for all solids to dissolve. This process was endothermic (the solution was cooled to 13 ° C. when the ambient temperature was 20 ° C.). A solution of ethyl bromoacetate (100 mL, 0.90 mol) dissolved in EtOAc (400 mL) was added dropwise over 1.5 hours. A white precipitate formed during the addition. Stir overnight (20 hours) at ambient temperature (18 ° C.).

The solid was collected by vacuum filtration and rinsed with a large amount of Et ₂ O. It was dried overnight at 45 ° C. under reduced pressure to obtain 3 as a white solid (356.3 g) in a yield of 92.6% (0.83 mol). ¹ H NMR was consistent with literature values.

This solid was dissolved in methylene chloride (3 L) and treated with 1 M NaOH (3.6 L) in a 12 L flask with vigorous stirring for 45 minutes. The organic phase was separated and the aqueous phase was extracted with the addition of methylene chloride (2 × 1 L). The organic phase was dried (MgSO ₄ ) and concentrated until the remaining volume was approximately 1 L. A small amount of material was removed and examined by ¹ H NMR and found to be consistent with literature values.

[1- (Ethoxycarbonyl) ethylidene] triphenylphosphonium iodide (5) ² (ACL-G29-2):
The material obtained with ACL-G29-1 was treated with iodomethane (64.0 mL, 1.03 mol) while the reaction flask was cooled in an ice bath. When the addition was complete (1 hour), the reaction mixture was checked by TLC (silica gel, 10% MeOH / CHCl ₃ ) and showed that a significant amount of starting material remained. The ice bath was removed and the reaction mixture was checked by TLC after 1.5 hours. Based on a decrease in the width of the main band (starting material becomes streaked), the reaction appeared to be complete. When the reaction mixture was concentrated on a rotary evaporator and most of the solvent was removed, the product began to foam and rose to the vapor duct. The phosphonium salt 5 that appeared was a very viscous syrup, but was stored as a methylene chloride solution for ease of handling. Due to the nature of 5, this material was not quantified.

[1- (Ethoxycarbonyl) ethylidene] triphenylphosphorane (6) ² (ACL-G29-2A):
A portion of 5 was dissolved in CH ₂ Cl ₂ (350 mL) and stirred vigorously with 1M NaOH (500 mL) for 45 min. The organic phase was separated and the aqueous phase was extracted with CH ₂ Cl ₂ (2 × 100 mL). The organic phases were combined, dried (MgSO ₄ ) and concentrated to give 6 as a yellow solid, 8.0 g. ¹ H NMR spectrum was consistent with literature values.

Fumaraldehyde bis (dimethylacetal) (8) ³ (ACL-G29-3):
A solution of furan (88.0 g, 1.29 mol) dissolved in anhydrous MeOH (650 mL) was cooled to −45 ° C. under N ₂ . A solution of bromine (68.0 mL, 1.32 mol) was added dropwise over 2.5 hours at a rate that maintained ≦ −45 ° C. The red solution was warmed to −10 ° C. over 2.5 hours and held there for an additional 2 hours. The reaction mixture was light amber. The addition of 5 g Na ₂ CO ₃ resulted in a significant amount of outgassing and an exotherm of 4 ° C. The reaction mixture was cooled with dry ice and the remaining Na ₂ CO ₃ (total 210 g) was added over 50 minutes. After maintaining overnight at −10 ° C. (11 hours), the ice bath was removed and the reaction mixture was allowed to warm to room temperature and stirred for 20 hours.

The resulting salt was removed by vacuum filtration, and the filtrate was vacuum distilled using a Vigreux column until about 150 mL was removed. More salt precipitated, causing a severe crash of the still. After filtration, an additional 150 mL was distilled and a larger amount of salt precipitated from the solution. Again, a fierce collision became a problem. The distiller was cooled and filtered, the filtrate was treated with Et ₂ O (400 mL), and the precipitate was removed by vacuum filtration. At least 120 g of salt was collected (initially harvested salt was discarded without quantification). Most of the Et ₂ O was removed at 25 ° C. using a rotary evaporator equipped with a water aspirator. Distillation was resumed using a Vigreux column and 8 was collected as 175.2 g of a clear colorless liquid having a boiling point of 86-92 ° C./9 torr (literature value 85-90 ° C./15 torr) (yield 76.9%). ¹ H NMR spectrum was consistent with the desired product. GC analysis: purity 81.9%.

Fumaraldehyde mono (dimethyl acetal) (9) ⁴ (ACL-G29-4):
Fumaraldehyde bis (dimethylacetal) 8 (5.29 g, 0.03 mol) was dissolved in acetone (120 mL). H ₂ O (1.80mL) and was successively added Amberlyst 15 (1.20 g). The resulting mixture was stirred vigorously for 5 minutes and then filtered to remove the resin. During this time, the solution turned from colorless to yellow. At room temperature, the filtrate is concentrated on a rotary evaporator, the wheat-colored residue is distilled on a Kugelrohr (37 ° C./200 mtorr), 9 is a yellow liquid 2 in a yield of 71.8%. Obtained as 80 g. A small amount of material was lost when the distiller first struck. ¹ H NMR spectrum was consistent with the desired product. GC analysis showed that the purity was 80%.

(ACL-G29-7):
Fumaraldehyde bis (dimethylacetal) 8 (72.1 g, 0.41 mol) was dissolved in acetone (1600 mL). H ₂ O (25.0 mL) and Amberlyst 15 (16.7 g, prewashed with acetone) were added. The mixture was stirred vigorously for 5 minutes and then filtered to remove acidic resin. The reaction mixture turned slightly yellow and its color was much lighter than previous large scale preparations. GC analysis indicated the presence of 34.5% product and 46.1% starting material. Further treated with resin for 5 minutes. GC analysis indicated the presence of 59.5% product and 21.7% starting material. It was further treated with resin for 10 minutes (total time 20 minutes). GC analysis indicated the presence of 73.9% product and 2.0% starting material. The filtrate was concentrated with a rotary evaporator at room temperature to obtain 54 g of a brown oily substance. Distillation under reduced pressure gave 34.48 g of a yellowish green oily substance. GC analysis showed a purity of 64.7% (8.22 min) and the presence of 17.5% (9.00 min) and 6.9% (9.14 min) of main impurities. The net recovery yield was 22.3 g (0.17 mol). Analysis of the initial cut by GC indicated that the material contained a very large amount of impurities.

(ACL-G29-13):
Amberlyst 15 (8.61 g) was stirred in acetone (100 mL) for 30 minutes and collected by filtration. Acetal 8 (35.0 g, 0.16 mol) was dissolved in acetonitrile (620 mL), and acidic resin and deionized water (10.0 mL, 0.55 mol) were added with mechanical stirring. When the reaction process was observed by TLC (hexane: Et ₂ O (10: 3)), most of the starting material was converted after 15 minutes. After 20 minutes, only trace amounts of dimethyl acetal were detected. The resin was removed by filtration and the filtrate was concentrated on a rotary evaporator at ≦ 40 ° C. The crude product was loaded onto a Biotage column (7.5 × 9.0 cm) and eluted with 15% Et ₂ O in hexanes to give 19.8 g (65% yield).

6,6-Dimethoxy-2-methylhexa-2,4-dienoate (10) ² (ACL-G29-5):
Ylide 6 (7.80 g, 22 mmol) was dissolved in methylene chloride (65 mL). A solution of fumaraldehyde mono (dimethyl acetal) 9 (2.80 g, 17 mmol) was added and the solution was stirred overnight. The solvent was removed by reducing the pressure with a rotary evaporator. ¹ H NMR of the crude product indicated the presence of the desired product. Upon standing, crystals grew (presumed to be triphenylphosphine oxide). This solid (14.1 g after drying by vacuum filtration) was slurried in petroleum ether and filtered. The filtrate was concentrated to give a yellow oily substance with a precipitated solid, which was dissolved in methylene chloride (15 mL), chromatographed using a Biotage 4 × 7.5 cm column, eluting with methylene chloride, 10 As a yellow oily substance (yield 50%). The ¹ H NMR spectrum of the yellow oily substance was consistent with literature values, but because traces of methylene chloride remained (0.75 equivalents), the material was placed on a rotary evaporator for 45 minutes. The mass decreased to 1.5 g (40.6% yield) and the methylene chloride resonance disappeared. The main peak of GC analysis is 12.6 minutes. 87.5% (held at 50 ° C. for 5 minutes and raised to a final temperature of 250 ° C. at 20 ° C./min).

(ACL-G29-6):
A solution of ylide 6 (59.2 g, 0.16 mol) dissolved in methylene chloride (650 mL) was cooled in an ice bath and a solution of 9 (25.7 g, 0.19 mol) was added. The solution was stirred overnight, leaving the ice bath to melt. TLC (hexane: Et ₂ O (10: 3)) showed that there were at least three other compounds that migrated very close to the product. Examination of the aldehyde by GC analysis showed a purity of 50.0%. The solvent was removed to give a solid / oil mixture.

(ACL-G29-8):
Ilide 6 (59.2 g, 0.16 mol) and acetal 9 (0.19 mol) were coupled in methylene chloride (1.1 L) and worked up as described above to give 80 g of a yellow green oil. It was. A portion of the crude reaction mixture (4.13 g of the original 80 g) was placed in a Kugelrohr and distilled at 50 ° C./250 mtorr. The colorless oil was concentrated to 2.28 g, but ¹ H NMR indicated that it was the starting aldehyde, while product 10 (1.85 g) remained in the still. Volatile components were removed from most of the crude product by a Kugelrohr distillation at 50 ° C./250 mtorr (net 35 g).

Ethyl 2-methyl-6-oxo - hexa-2,4-dienoate ^{(11) 2 (ACL-G29-9} ):
Acetal 10 (ACL-G29-8, 1.85 g, 9 mmol) obtained from the pre-distiller was dissolved in acetone (33 mL). Deionized water (0.50 mL) and Amberlyst 15 resin (0.35 g, prewashed with acetone) were added. The mixture was stirred for 20 minutes. Filtration and concentration on a rotary evaporator gave 1.53 g of a yellow-green oil. Chromatography was performed using a Biotage column (4.5 × 7 cm) eluting with 15% Et ₂ O in hexane. Although this system was incompletely separated, 0.32 g of the major component was isolated and analyzed. ¹ H NMR spectrum was consistent with literature data and IR (1711, 1682 cm ⁻¹ ) was consistent with the desired product. 95.6% for GC. An additional 0.35 g was recovered, but a less polar material and a higher material cross-mixed. ¹ H NMR spectrum indicated a fairly pure material. 90.6% for GC. Yield: 42%.

Diethyl 2,7-dimethylocta-2,4,6-triene-1,8-dioate (12) ² (ACL-G29-10):
The aldehyde 11 (0.65 g, 3.5 mmol) obtained in G29-9 was dissolved in methylene chloride and stirred with a magnetic stirrer. Ylide (1.59 g, 4.4 mmol) was added. The pale yellow-green solution turned to a darker yellow within a few minutes. TLC after 10 minutes showed that the starting material was almost completely consumed. After stirring for 20 hours, the reaction mixture (brown solution) was filtered through a pipette partially filled with silica gel. The filtrate was concentrated to give a brown solid. The solid was dissolved in 5% Et ₂ O in hexane containing a small amount of CHCl ₃ . Chromatography was performed using a Biotage column (4 × 7.5 cm), eluting with 5% Et ₂ O in hexane. The main product was isolated as a white crystalline solid 045g (yield 50%). ¹ H NMR spectrum was consistent with literature data.

(ACL-G29-14):
12 was further prepared as described above, and after purification by chromatography, 21.8 g was obtained (81.6%). ¹ H NMR spectrum was consistent with the desired product.

2,7-dimethylocta-2,4,6-triene-1,8-diol (13) ² (ACL-G29-11):
Diester 12 (0.45 g, 1.8 mmol) was placed in anhydrous hexane (15.0 mL). Some of the material appeared to dissolve, but the mixture was quite turbid. When the mixture was cooled in a -78 ° C bath, more material appeared to precipitate out of solution. Neat DIBAL-H (2.50 mL) was dissolved in anhydrous hexane (total volume 10.0 mL), but when the diester was cooled in a dry ice bath, a portion of the DIBAL-H solution was inadvertently (About 2 mL) has been aspirated into the reaction mixture. Additional DIBAL-H solution was added until a total of 5.0 mL (6.7 mmol) was added. It was allowed to warm CO ₂ bath. After stirring for 2 hours and 50 minutes, TLC indicated that the diester was completely consumed. The bath temperature was adjusted to −20 ° C. and warmed to 0 ° C. over 20 minutes. Treated with H ₂ O / silica gel mixture (2 mL / 7 g) for 30 min. K ₂ CO ₃ and MgSO ₄ were added. The solid was removed by filtration and rinsed thoroughly with methylene chloride. Concentration gave 0.14 g of white solid (yield 50%). Note that TLC R _f = 0.21 (5% MeOH / CHCl ₃ ) is very polar. Rinsing with methylene chloride may not be sufficient to recover all the product. ¹ H NMR spectrum was consistent with literature values.

(ACL-G29-15):
The diester (5.4 g, 21 mmol) was placed in anhydrous hexane (175 mL, very poor solubility), cooled in a −78 ° C. bath and a solution of DIBAL-H (14.5 mL in 50 mL anhydrous hexane) for 35 minutes. Was processed. Vigorous gas evolution was observed during the addition. The color of the slurry first changed from white to dark yellow, and the color faded upon further addition of DIBAL-H. After warming to −40 ° C. over 2 hours, it was transferred to a −28 ° C. bath and left overnight. The reaction mixture was treated with a homogeneous mixture of H ₂ O / silica gel (4 mL / 14.4 g) for 30 minutes. MgSO ₄ (7.5 g) and K ₂ CO ₃ (5.1 g) were added and the reaction mixture was removed from the cooling bath. Stir for 20 minutes and then filter through a sintered glass funnel. The resulting solid was washed with methylene chloride. This formed a considerable amount of precipitate. The precipitated solid was dissolved by heating in a rotary evaporator. The solid remaining in the sintered glass funnel was washed with EtOAc (4 × 75 mL) and the filtrate was concentrated.

By rinsing with CH ₂ Cl ₂ , 1.7 g of a pale yellow solid was obtained. ¹ H NMR was consistent with literature values. By rinsing with EtOAc, 1.0 g of an off-white solid was obtained. ¹ H NMR was consistent with literature values. Total recovered amount 2.7 g, yield 75%.

(ACL-G29-17):
The diester (16.4 g, 6.5 mmol) was stirred in anhydrous hexane (500 mL) under N ₂ and cooled to -78 ° C. A solution of DIBAL-H (45 mL, 253 mmol) dissolved in hexane (150 mL) was added over 1 hour. Warm to −30 ° C. and stir overnight (17.5 hours total). A homogeneous mixture of H ₂ O / silica gel (12.3 g / 43.7 g) was added and the mixture was stirred manually for 45 minutes. K ₂ CO ₃ (15.5 g) and MgSO ₄ (23.5 g) were added. Stir for another 30 minutes. Filtration through a sintered glass funnel, rinsing with methylene chloride (precipitation is likely due to evaporative cooling) and the filtrate was concentrated. The solid was rinsed several times with EtOAc (approximately 100 mL each, 2 L total volume) and pooled with the original filtrate. Concentration gave a yellow solid, 8.9 g, crude yield 81%. ¹ H NMR spectrum was consistent with the desired product.

2,7-dimethylocta-2,4,6-triene-1,8-dial (14) ² (ACL-G29-12):
A slurry of MnO ₂ (7.80 g, 90 mmol) was cooled in an ice bath under N ₂ . A solution of diol 13 (0.14 g, 0.8 mmol) was pipetted as an acetone solution (5.0 mL). An additional 2.0 mL of acetone was used to rinse the flask and complete the transfer. The reaction mixture was stirred while the ice bath was allowed to melt overnight. The solid was removed by filtration through Hyflo and concentrated to give a yellow solid. The material was dissolved in 10% Et ₂ O / hexane using a minimum amount of CHCl ₃ and applied to a silica gel column (30 × 190 mm) and eluted with 10% Et ₂ O / hexane. The product could be tracked as a yellow band as it eluted, and 14 was isolated as a pale yellow solid 37 mg (26% yield). ¹ H NMR spectrum was consistent with literature values.

(ACL-G29-16):
A solution of diol 13 (2.70 g, 16 mmol) dissolved in acetone (500 mL) was cooled in an ice bath under N ₂ . MnO ₂ (60.0g, 0.69mol) were added in several times in 20 minutes. The reaction mixture was stirred overnight, leaving the ice bath to melt. The reaction mixture was filtered through Hyflo and the filtrate was concentrated to give 1.6 g of yellow solid (crude yield 61%). ¹ H NMR was consistent with literature values. The crude yellow solid was dissolved in methylene chloride (added with a small amount of 10% Et ₂ O in hexane) and charged to a Biotage silica gel column (4 × 7.5 cm). First elute with 10% ether in hexane (1 L) and then increase the polarity to 15% Et ₂ O (1 L) and 20% Et ₂ O (0.5 L). 1.0 g of a yellow solid was recovered (yield 38%). ¹ H NMR spectrum was consistent with the desired product.

(ACL-G29-21):
The solution under _{N 2} acetone diol dissolved in (500mL) (9.31g, 60mmol) , cooled in an ice bath. MnO ₂ (100g, 1.15mol) was added and left unattended and the ice bath melts and the mixture was stirred overnight. When checked by IR after 24 hours, a significant amount of product was formed, but still a significant amount of alcohol was present. An additional 50 g of oxidant was added and stirring continued for another night. A portion of the reaction mixture was filtered and checked by ¹ H NMR and based on consumption of starting material, the reaction appeared complete. The remainder of the reaction mixture was filtered through a pad of Hyflo and rinsed thoroughly with acetone. Concentration gave a dark yellow solid. It was azeotroped once with 40 mL of benzene and then dried in vacuo at 40 ° C. for 5 hours and further at room temperature overnight. 5.28 g was recovered (yield 58%). ¹ H NMR and IR spectra were consistent with the desired product.

Methyl tiglate (16):
Solution of tiglic acid 15 (89.8 g, 0.9 mol) and concentrated sulfuric acid 5 mL (0.09 mol) dissolved in 900 mL of methanol in a 2 L three-necked flask equipped with an overhead stirrer, a condenser and a thermometer Was heated to reflux for 20 hours. The solution was cooled to 25 ° C. and excess methanol was removed on a rotary evaporator at 30 ° C. and 27 inches Hg vacuum. GLC analysis of the recovered methanol distillate showed the presence of product in the overhead. The obtained two-phase wheat concentrate was put into 500 mL of ethyl ether and washed successively with 250 mL of water, 250 mL of 10% aqueous sodium hydrogen carbonate solution and 250 mL of saturated brine. The ether solution was dried over anhydrous potassium carbonate, filtered, and the solvent was removed on a rotary evaporator at 25 ° C. and 27 in Hg under reduced pressure to obtain 43.6 g of crude methyl tiglate as an almost colorless oily substance (42% yield). . GLC analysis showed one main volatile product with a retention time of 2.7 minutes versus a retention time of 3.8 minutes for the starting tiglic acid. Proton NMR in CDCl ₃ showed the expected signal with traces of ethyl ether contamination. 1.79 ppm (d, 3H), 1.83 (s, 3H), 3.73 (s, 3H), 6.86 (q, 6.6 Hz). IR (neat with KBr): ester carbonyl at 1718 cm ⁻¹ . This oil was used as such in the next step.

Methyl γ-bromotiglate (17) ⁵ :
In a 1 L four-necked flask equipped with an overhead stirrer, thermometer and condenser, crude methyl tiglate (43.6 g, 0.38 mol) in 500 mL of carbon tetrachloride, N-bromosuccinimide (68 g,. 38 mol) and 70% benzoyl peroxide (5.34 g, 0.015 mol) were heated to reflux for 2 hours. After cooling to 20 ° C., insoluble succinimide (38.1 g, recovery rate 100%) was removed by suction filtration. The filtrate was washed 3 times with 250 mL water, dried over MgSO ₄ and then removed on a rotary evaporator at 25 ° C. under 26 in Hg vacuum to yield 78.8 g of a yellow oil. To obtain a complex spectrum of proton NMR of the oil was dissolved in CDCl _3. The methylene proton of the desired γ-bromo ester was assigned to a doublet centered at 4.04 ppm (8.6 Hz) and the same proton of the α-bromo isomer was assigned to a single line of 4.24 ppm. The following composition (mol%) was suggested from these signals and the proton integral value of 1.6 to 2.0 ppm methyl multiple line.
γ-bromoester: 59%
α-bromoester: 26%
Starting material: 15%

  This crude oil was used in the next step without further purification.

  This reaction was also carried out at 0.05 molar scale, using only 0.87 equivalents of N-bromosuccinimide, with the same conditions. The composition of this crude oil was estimated as 52% γ-bromo ester, 24% α-bromo ester and 23% unreacted methyl tiglate based on its proton NMR spectrum. GLC analysis of this oil was a little more complicated, indicating the presence of other minor components.

Triphenylphosphonium salt of methyl γ-bromothyglycinate (19) ⁶ :
In a 2 L four-necked flask equipped with a thermometer, a 100 mL constant-pressure addition funnel, and a condenser connected to a static nitrogen system, 350 mL of benzene was stirred and dissolved with crude methyl γ-bromotiglate (78.8 g). To this solution, a solution of triphenylphosphine (95 g, 0.36 mol) dissolved in 350 mL of benzene was added dropwise over 1.75 hours. The temperature of the mixture exothermed slightly from 24 ° C to 27 ° C, the others were ambient conditions. After the addition, the reaction was stirred vigorously overnight to give a white solid slurry containing a yellowish gum-like substance attached to the wall of the flask. The white solid was suction filtered through a sintered glass funnel without disturbing the yellowish gum. The flask was washed twice with 100 mL of benzene and poured onto the filter. The filter cake was washed with 50 mL of benzene and then twice with 50 mL of hexane. The wet cake was dried in an oven at ambient temperature for 5.5 hours. The dried white powder (93 g, mp = 125 ° C. dec) was dissolved in 150 mL of acetonitrile while heating to obtain a transparent yellow solution. The ethyl acetate (300 mL) was added to the hot solution, and after about 100 mL of ethyl acetate was added, the product began to crystallize. The flask was stored in the refrigerator overnight. The product was filtered off with suction and washed with a minimum amount of acetonitrile and ethyl acetate (1: 2). 45.0g. mp = 187-190 ° C. (decomposition). Literature mp = 183 ° C. (decomposition).

  The gummy solid in the reaction flask was recrystallized from 10 mL acetonitrile and 20 mL ethyl acetate. Similarly, further solids were precipitated from the benzene mother liquor overnight. These solids were filtered and recrystallized in the same manner. Both samples were refrigerated for 2 hours and suction filtered to give an additional 13.3 g of product.

The benzene filtrate was removed on a rotary evaporator and the yellow oil was taken up in 10 mL acetonitrile and precipitated with 20 mL ethyl acetate. This slurry was stored in the refrigerator overnight to give an additional 4.6 g of product as a white solid. m. p. 185-187 ° C (decomposition). The total yield of the desired phosphonium salt as a white solid was 62.9 g, ie 36.2% based on crude methyl tiglate. Proton NMR (CDCl ₃ , TMS) ppm 1.55 (d, 4 Hz, 3H), 3.57 (s, 3H), 4.9 (dd, 15.8, 7.9 Hz, 2H), 6.55 (broad) q, 6.6-7.9 Hz, 1H), 7.4-7.9 (m, 15H). Phosphorus NMR with proton decoupling (CDCl ₃ , 5% H ₃ PO ₄ aqueous solution, coaxial external standard) 22.08 ppm. Partial carbon _{NMR (CDCl 3): C O} 2 CH 3 (166.6ppm, d, J CP = 3Hz), olefin _{C H (117.5ppm, d, J} CP = 86.1Hz), CO 2 C H 3 (52.0 ppm), Ph ₃ P— C H ₂ (25.4 ppm, d, J _CP = 50.6 Hz) and C H ₃ (13.4 ppm, d, J _CP = 2.4 Hz). Partial IR (KBr pellet): ester carbonyl at 1711 cm- ¹ .

(3-Carbomethoxy-2-butene-1-ylidene) triphenylphosphorane (20) ⁶ :
In a 5 L five-necked flask equipped with an overhead stirrer, addition funnel and thermometer, a solution of sodium hydroxide (5.12 g, 0.128 mol) dissolved in 250 mL of water was dissolved in 2500 mL of water with γ-bromotiglin. To a vigorously stirred solution of methyl triphenylphosphonium salt (58.3 g, 0.128 mol) was added dropwise at 25 ° C. over 41 minutes. The resulting yellow slurry was stirred at room temperature for 10 minutes and then filtered with suction. The filter cake was washed with 1800 mL of water and then completely dried on the filter under a nitrogen atmosphere. The yellow solid was then dried overnight in a vacuum desiccator containing P ₂ O ₅ at room temperature and 27 ″ Hg vacuum. 35.3 g (yield 73.7%). Mp = 145-150 ° C. Document mp = 145-165 ° C. Phosphorus NMR in proton-coupled CDCl ₃ showed two peaks at a ratio of 93: 7 at 17.1 ppm and 21.1 ppm Proton NMR (CDCl ₃ , TMS) ppm 1.89 (s, 3H), 3.58 (s, 3H), 7.3-7.8 (m, 17H) A small but detectable singlet at 1.74 ppm also appears in this spectrum This was attributed to impurities, and this solid was used in the next step without further purification.

Dimethyl crocetinate (21) ⁶ (ACL-G29-18):
Dialdehyde 14 (0.48 g, 2.9 mmol) was placed in a 100 mL round bottom flask. Benzene (20 mL) was added and stirred with a magnetic stirrer to dissolve the solid. The ylide was added and the compound was washed into the flask using an additional 10 mL of benzene. Warmed and refluxed vigorously for 6 hours. The reaction mixture was cooled overnight. Contrary to literature reports, only a very small amount of solid was formed. The reaction mixture was concentrated and the residue was taken up in MeOH (30 mL) and boiled for 30 minutes. Cooled to ambient temperature and the resulting solid was collected by vacuum filtration. An NMR sample was prepared by dissolving 20 mg in 0.5 mL of CDCl ₃ , somewhat surprisingly, at this time it had to be heated with a heat gun to completely dissolve. ^{A 1} H NMR spectrum was recorded and found to be consistent with the desired product. The remaining material was dissolved in hot benzene and filtered, the filtrate was concentrated, taken up in MeOH and cooled in an ice bath to collect 334 mg of red solid (33% yield). The solubility of this material did not appear to be any higher than the originally isolated material.

(ACL-G29-18A):
Dialdehyde 14 (5.78g, 35mmol) was dissolved in benzene (300 mL) under _{N 2.} Ylide 20 (35.3 g, 94 mmol) was added and the resulting mixture was warmed to reflux for 6 hours to form a dark red solution. After the reaction mixture was allowed to cool overnight, the red solid was collected by vacuum filtration and rinsed with methanol. The solution was transferred to 500 mL of RBF and refluxed with about 65 mL of methanol for 30 minutes. Cooled and collected a red solid. Rinse with cold methanol and vacuum dry to give 21 (3.00 g) as a red solid. ¹ H NMR and IR spectra were consistent with the desired product.

The original filtrate (from the reaction mixture) was concentrated on a rotary evaporator and the dark residue was taken up in 100 mL of methanol and refluxed for 40 minutes. Cool in an ice bath and collect the red solid by vacuum filtration. Rinse with cold methanol and vacuum dry to give 21 (1.31 g) as a red solid. ¹ H NMR spectrum was consistent with the desired product.

The filtrates were pooled, concentrated, taken up in 75 mL methanol and allowed to stand overnight at room temperature. 0.38 g of a red solid was recovered by vacuum filtration. ¹ H NMR spectrum was consistent with the desired product.

  In addition, a large amount of solid formed in the filtrate. Isolation by vacuum filtration gave 0.127 g of a red solid. IR was consistent with the above. Total recovered amount: 4.89 g, 39% yield.

Trial of saponification using THF / NaOH (ACL-G29-19):
A stirred suspension of diester 21 (100 mg, 0.28 mmol) and 1N NaOH (0.56 mL, 2 eq) in THF (2 mL) was added. Stir overnight at room temperature. TLC showed the presence of starting material only. Heated to reflux, but remained unchanged after several hours. THF (6 mL) was added to dissolve more of the solid, but it did not seem critical. Continue to reflux overnight. A larger amount of THF was added (about 6 mL, TLC showed the presence of starting material only) and refluxed overnight. Concentrated and checked by ¹ H NMR, but only starting material (based on integral of methyl and methyl ester). It was dissolved in pyridine (10 mL) while heating with a heating mantle. 2.5N NaOH (1.0 mL) was added. The dark orange solution turned red after a few minutes. The heating mantle was removed and solids began to form and the mantle was used again for 30 minutes and then stirred at room temperature overnight. Concentrated in high vacuum. The residue was insoluble in chloroform, DMSO, and pyridine, and was slightly soluble in H ₂ O. IR (Nujolmur) showed the C = O absorption characteristic of the starting material.

Saponification with 2.5N NaOH and THF (ACL-G29-20):
Diester 21 (37 mg, 0.10 mmol) was weighed into a flask and stirred in diethyl ether (4 mL). The solvent had an orange color but solids were still present. 1 mL of 2.5N NaOH was added and warmed to reflux. After half an hour, most of the ether had evaporated. This was replaced with THF (3 mL) and reflux was continued for several hours. The solid was collected by vacuum filtration, rinsed with deionized water and then dried in a vacuum dryer. IR showed the presence of starting material only.

Saponification with 40% NaOH (1) (ACL-G29-22):
Diester 21 (32 mg, 8.9 mmol) was weighed into a flask and stirred in methanol (1.5 mL). The solvent had an orange / red color but solids were still present. 40% NaOH 1.5 mL was added and warmed to reflux for 17 hours. After cooling to room temperature, the orange solid was collected by vacuum filtration and rinsed with deionized water. Vacuum drying at 40 ° C. gave 1 as an orange powder 21 mg (59%). IR (KBr pellet) 3412, 1544, 1402 cm- ¹ . This compound is probably hygroscopic. The high field shift of carbonyl is consistent with conjugation.

(ACL-G29-22A):
Repeated with diester 1 (35 mg) and refluxed for 15 hours. The reaction mixture was cooled in an ice bath, collected by vacuum filtration and washed with cold deionized water. Vacuum dried at 40 ° C. 1 was recovered as an orange solid 25.5 mg (65%).

(ACL-G29-23):
Diester 21 (0.48 g, 1.3 mmol) was placed in methanol (15.0 mL) and 40% sodium hydroxide (15.0 mL), heated to reflux. The heterogeneous red mixture turned orange after about 2 hours. Heating was stopped after 6 hours and the mixture was allowed to cool overnight. The orange solid was collected by vacuum filtration and washed with cold deionized water. Vacuum drying gave 0.36 g of a brittle orange solid (68% yield).

(ACL-G29-24):
Diester 21 (1.10 g, 3.1 mmol) was placed in a 100 mL recovery flask and heated to reflux in methanol (20 mL) and 40% NaOH (20 mL) for 12 hours. After cooling in an ice bath, the orange solid was collected by vacuum filtration and rinsed with deionized water. Vacuum drying gave 1.4 g (100%). _{C 20 H 22 O 4 Na 2} -0.4H 2 O about Calcd: C: 63.29, H: 6.05 , Na: 12.11, H 2 O: 1.90. Found: C: 63.41, H: 6.26 , Na: 11.75, H 2 O: 1.93.

(ACL-G29-25):
Diester 21 (3.00 g, 8.4 mmol) was refluxed in methanol (80 mL) and 40% NaOH (60 mL) for 12 hours. The product was isolated as an orange solid as described above (2.7 g, 80%). _{C 20 H 22 O 4 Na 2} -0.4H 2 O about Calcd: C: 63.29, H: 6.05 , Na: 12.11, H 2 O: 1.90. Found: C: 63.20, H: 6.00 , Na: 11.93, H 2 O: 1.81. Samples ACL-G29-23, -24 and 25 were ground in an agate mortar and combined as ACL-G29-A.

References:
1. E. Buchta and F.A. Andrew, Naturewiss. 1959, 46, 74.
2. F. J. et al. H. M.M. Jansen, M.M. Kwestro, D.C. Schmitt, J.M. Lugtenburg, Recl. Trav. Chim. Pays-Bas 1994, 113, 552.
3. R. Green, H.C. Tourbah, R.A. Carrie, Tetrahedron Letters 1986, 27, 4983.
4). G. M.M. Coppola, Syn. Commun. 1984, 1021.
5). D. S. Letham and H.C. Young, Phytochemistry 1971, 10, 2077.
6). E. Buchta and F.A. Andrew, Chem. Ber. 1960, 93, 1349.

(Example 2: Synthesis of transpotadium norbixinate)

  Transpotadium norbixinate is synthesized by coupling a symmetrical C20 dialdehyde containing a conjugated carbon-carbon double bond with [1- (ethoxycarbonyl) methylidene] triphenylphosphorane. The preparation of this compound is similar to the preparation described above for transsodium crocetinate, except that the furan starting material is exchanged for the appropriate ring structure. The product is then saponified using a KOH / methanol solution.

Example 3: Synthesis of longer chain BTCS

The above compound conjugated carbon - is synthesized by adding a symmetrical C ₁₀ dialdehyde which contains carbon-to-carbon double bonds in excess of [3-carbomethoxy-2-buten-1-ylidene] triphenylphosphorane. The preparation of this compound is similar to the preparation described above for transsodium crocetinate, except that the furan starting material is exchanged for the appropriate ring structure. The trans 40-carbon product is then isolated using techniques such as chromatography. The product is then saponified using a NaOH / methanol solution.

(Example 4: TSC by inhalation)
TSC was given to rats by the inhalation route. Ten rats received TSC directly into the lungs. This was done by inserting a tube into the trachea and spraying with 0.2 mL of TSC solution (TSC dissolved in dilute sodium carbonate solution) with about 3-6 mL of air. For all doses studied (0.5-2 mg / kg), approximately 20% of the drug was present in the bloodstream within 1 minute after drug administration. For doses of 0.8-1.6 mg / kg, the drug was present in the bloodstream for at least 2 hours.

(Example 5: Improved synthesis method)
Preparation of 2-butenyl-1,4-bisphosphonate tetraethyl:

  A 250 mL three-necked flask was equipped with a Teflon-coated thermocouple, a 60 mL constant pressure addition funnel, and a simple distillation head. Under a nitrogen atmosphere, neat triethyl phosphite (59 mL, 0.344 mol) was heated using a heating mantle controlled at 140 ° C. with a JKem controller. A solution of trans-1,4-dichloro-2-butene (26.9 g, 0.215 mol) and triethyl phosphite (35 mL, 0.204 mol) was added dropwise at 134-144 ° C. over 93 minutes. The resulting clear solution was kept at 140 ° C. under nitrogen. After 37 minutes, gas chromatography on an aliquot (1 drop) in 1 mL of ethyl acetate showed the presence of the desired product, intermediate product and two starting materials.

After 15.5 hours at 140 ° C., gas chromatography on a constant volume (1 drop in 0.5 mL EtOAc) showed the presence of the desired product, but no starting dichloride and intermediate products were detected. After 16 hours, the slightly yellow solution was cooled to room temperature under nitrogen. Using a Kugelrohr further equipped with a 2-valve receiver and a valve cooled in a dry ice-acetone bath, the slightly yellow oily substance was distilled at 25 to 100 ° C. and 0.1 to 0.2 torr to obtain a colorless oily substance (14 .8 g) was obtained as the initial cut. Gas chromatography showed that only the product was present in the Kugel roll pot. This pale amber oily substance was distilled using a Kugelrohr at 140 ° C. and 0.1 to 0.15 torr to obtain a distillate as a colorless oily substance 66.45 g (yield 94.1%). Gas chromatography showed the presence of only one volatile component. GC-MS analysis gave a small molecule ion at 328 m / z and a base ion (loss of PO ₃ Et ₂ ) at 191 m / z, indicating that this component was the desired product. Proton NMR was consistent with the desired product. Carbon NMR was also consistent with the desired bis (phosphonic acid diester) and showed only long range (W-coupling) to allyl carbon and normal carbon-phosphorus coupling.

  Pot residue: 0.8 g pale yellow oil.

Preparation of 1,1,8,8-tetramethoxy-2,7-dimethyl-2,4,6-octatriene:

  Magnetically trans-2-butenyl-1,4-bisphosphonate tetraethyl (3.3 g, 10.0 mmol) and pyruvic aldehyde dimethyl acetal (2.6 mL, 21.5 mmol) in 10 mL of toluene and 10 mL of cyclohexane under nitrogen atmosphere The mixture with a stirrer was treated sequentially with anhydrous potassium carbonate (10.2 g, 73.8 mmol) and powdered sodium hydroxide (1.25 g, 31.2 mmol). The solution immediately turned yellow. The resulting slurry was stirred at ambient temperature under nitrogen. The reaction slowly exothermed and reached a maximum of 38 ° C. after about 25 minutes. In addition, a gummy precipitate was formed, which adversely affected stirring with a magnetic stirrer. After 2.5 hours, gas chromatography of a constant amount (1 drop in 0.5 mL toluene) of a yellow-orange solution showed the presence of two starting materials and three other novel components.

After 16.75 hours at ambient temperature, gas chromatography of an aliquot of orange solution (1 drop in 0.5 mL toluene) showed the presence of only a small amount of starting bis (phosphonic diester). The resulting orange mixture with a gummy mass (not stirrable) was cooled in an ice bath and quenched with 100 mL of 10% aqueous NaCl. The solid was dissolved in this aqueous solution by working with a spatula. The mixture was then extracted with 200 mL of ether: hexane (1: 1). The organic phase was washed successively with 10% NaCl aqueous solution (200 mL) and saturated brine (100 mL). The colorless organic phase was dried over Na ₂ SO ₄ . Gas chromatography showed the presence of three major components, but no starting bis (phosphonic acid diester) was detected. The thin layer chromatogram showed two major spots and one minor spot. Na ₂ SO ₄ was removed by suction filtration and washed with ether. The filtrate was concentrated at 35 ° C. with a rotary evaporator to give 1.8 g of a colorless oil. GC-MS analysis gave a molecular ion at 256 m / z and a base ion [(MeO) ₂ CH ⁺ ] at 75 m / z, indicating that the three main volatile components are isomeric products. . Proton NMR was also consistent with the presence of a mixture of isomeric products along with other unidentified impurities. Yield of crude product = 70.3%.

Preparation of 1,1,8,8-tetramethoxy-2,7-dimethyl-2,4,6-octatriene:

A mixture obtained by mechanically stirring trans-2-butenyl-1,4-bisphosphonate tetraethyl (63.2 g, 0.19 mol) and pyruvaldehyde dimethyl acetal (50 mL, 0.41 mol) in 200 mL of toluene and 200 mL of cyclohexane. Were treated sequentially with anhydrous potassium carbonate (196 g, 1.42 mol) and powdered sodium hydroxide (24.0 g, 0.60 mol). The solution immediately turned yellow. The resulting slurry was stirred at ambient temperature under nitrogen. The reaction exothermed to 61 ° C. after about 11 minutes, and the stirred mixture was cooled in an ice bath to reduce the temperature to 35 ° C. After 4.7 hours at 29-35 ° C., gas chromatography on a constant volume (3 drops in 0.5 mL toluene) showed no starting bis (phosphonate) present. After about 5 hours, the mixture was cooled to 13 ° C. in an ice bath, but when 400 mL of 10% aqueous sodium chloride solution was added, the temperature rose to 30 ° C. Further 10% aqueous sodium chloride solution (1500 mL) was added and the mixture was extracted with 3000 mL ether: hexane (1: 1). The yellowish organic phase was washed successively with 10% aqueous sodium chloride solution (2 × 1000 mL) and saturated brine (1000 mL). The yellowish organic phase was dried over Na ₂ SO ₄ , filtered and concentrated on a rotary evaporator at 30 ° C. to give 43.4 g of a pale yellow oil. Gas chromatography showed the presence of three major components comprising 89% of the mixture, but no starting bis (phosphonate) was detected. TLC analysis showed the presence of one major component and three minor components.

  Proton NMR indicated the presence of isomeric product and toluene. The oil was evaporated for an additional 30 minutes at 50 ° C. and 0.2 torr using a Kugelrohr (31.9 g). Proton NMR showed the presence of isomeric bis (acetal) product, but no toluene was detected.

  Yield = 65.5%.

Preparation of 2,7-dimethyl-2,4,6-octatrienedial with higher payload:

Crude 1,1,8,8-tetramethoxy-2,7-dimethyl-2,4,6-octatriene isomer in tetrahydrofuran (160 mL), water (80 mL) and glacial acetic acid (320 mL) under a nitrogen atmosphere. 31.9 g, 124.4 mmol) was heated to 45 ° C. with a heating mantle controlled by a JKem controller via a Teflon-coated thermocouple (9:03 am). After about 30 minutes, the mixture exothermed to a maximum of 54 ° C and then returned to the set temperature of 45 ° C. After 3 hours, gas chromatography on a constant volume (3 drops in 0.5 mL THF) showed the presence of some residual starting material, two main products, and one by-product. The yellow reaction solution was cooled to 21 ° C. in an ice bath and then diluted with ether: dichloromethane (4: 1) (2000 mL). Then, this solution was sequentially washed with 20% NaCl aqueous solution (2000 mL × 2), 20% NaCl aqueous solution: 1M NaOH aqueous solution (4: 1) (2000 mL × 3) ¹ and 20% NaCl aqueous solution (1000 mL × 2) [ ¹ : Acetic acid appears to have been removed by the first two washes, as evidenced by neutral pH. The third wash turned red, but it was still basic, suggesting that the by-product was removed]. Dry the yellow organic phase over MgSO _4, filtered, and concentrated on a rotary evaporator to give a yellow solid 18.9 g. Gas chromatography showed the presence of one major component and one minor component, starting bis (acetal). TLC analysis showed the presence of more polar impurities as one main spot and several side spots. This solid was dissolved in 250 mL of refluxing methanol, cooled to room temperature, and then cooled in an ice bath for 1 hour. The obtained slurry was subjected to suction filtration to obtain 14.15 g of a yellow cotton needle-like substance. Gas chromatography showed the presence of a 95: 5 mixture of isomeric dialdehydes. The solid was recrystallized once more with 200 mL of refluxing methanol, cooled to room temperature and then cooled in the refrigerator overnight.

  This slurry was suction filtered and washed with methanol cooled in a freezer to obtain 11.2 g of a yellow needle-like substance. Gas chromatography showed the presence of a 97: 3 mixture of isomeric dialdehydes. TLC analysis showed one spot. The acicular material was dried in a vacuum dryer at 45 ° C. for 160 minutes until a constant weight (10.75 g) was reached.

Uncorrected mp = 154-156 ° C. Document ² mp = 161-162 ° C. [ ² : Dictionary of Organic Compounds. Verson 10: 2, September 2002]. Proton NMR and carbon NMR were consistent with the desired symmetric dialdehyde.

  The two methanol filtrates obtained from recrystallization were combined. Thin layer chromatograms showed the presence of product and other impurities. As shown below, the filtrate was concentrated to collect various crops.

Crop 2 and 3: These crops were combined and dissolved in 20 mL of refluxing ethyl acetate, cooled to room temperature, and then cooled in a freezer for 1 hour. The slurry was suction filtered and washed with ethyl acetate cooled in a freezer to obtain a yellow needle-like material (1.95 g). Gas chromatography showed the presence of a 86:14 mixture of isomers. This solid was recrystallized once more in ethyl acetate (10 mL) to give yellow needles (1.55 g). Gas chromatography showed the presence of isomers in a 92: 8 ratio. A third recrystallization from ethyl acetate (10 mL) gave 1.25 g of yellow needles. mp = 152-154 ° C. Gas chromatography showed an isomer ratio of 96: 4. Proton NMR confirmed the desired dialdehyde. GC-MS analysis showed a prominent M ⁺ ion at 164 m / z and a base ion at 91 m / z, consistent with the desired dialdehyde.

  The ethyl acetate filtrate was combined with the yellow solid (harvest 4) obtained from the methanol filtrate and concentrated on a rotary evaporator to give 6.0 g of a yellow solid. Gas chromatography showed the presence of a 53:34 mixture of the two isomers along with other impurities.

  This solid was dissolved in 100 mL of dichloromethane and Davisil grade 643 silica gel (33.5 g) was added. The mixture was removed on a rotary evaporator at 35 ° C. The silica gel with adsorbed material was then added to the sample introduction module for the Biotage system. The module already contained a glass wool plug and a layer of sand. Next, a filter paper was placed on the silica gel. The Biotage 75S column was pre-wetted with the solvent mixture at a radial compression pressure of 35 psi and a solvent pressure of 20 psi. The column was eluted with hexane: ethyl acetate (85:15) (6000 mL). A 1000 mL void volume was collected including the pre-moistened stage. 250 mL fractions were collected and combined based on thin layer chromatogram analysis. These fractions were concentrated on a rotary evaporator at 35 ° C. as shown below.

  Fractions 5 to 10: The yellow solid was slurried in hexane and suction filtered to obtain 2.5 g of a bright yellow solid. Gas chromatography showed the presence of a 67:33 ratio of dialdehyde isomer mixture.

  Total yield 96-97%. E, E, E-dialdehyde = 10.75 + 1.25 = 12.0 g (yield 58.8%).

Isomerization of 2,7-dimethyl-2,4,6-octatrienedial using para-toluenesulfinic acid:

Under a nitrogen atmosphere, a 2: 1 isomer mixture of 2,7-dimethyl-2,4,6-octatrienedial and its off isomer (2.5 g, 15.2 mmol), 4-toluenesulfinic acid (0. 35 g, 2.2 mmol) and 50 mL of anhydrous 1,4-dioxane were heated to reflux for 15 minutes. Fixed amount (7 drops) ether: dichloromethane (4: 1) was diluted with 0.5 _mL, was dried over K 2 CO _3. Gas chromatography showed the presence of a 91: 9 mixture of the desired and off isomers.

After cooling at room temperature overnight, the resulting slurry was dissolved in 100 mL ether: dichloromethane (4: 1), water (50 mL × 3), 0.2 M aqueous NaOH (50 mL), water (50 mL × 2) and saturated. Washed sequentially with brine (50 mL × 3). After phase separation, the remaining lag layer was dissolved in dichloromethane. The combined organic phase was dried over MgSO ₄ , filtered and concentrated on a rotary evaporator at 40 ° C. to give 2.2 g of an orange solid. Gas chromatography showed the presence of the desired dialdehyde to off isomer in a ratio of 93: 7. This solid was slurried in hexane and suction filtered to give 2.15 g of an orange solid. After cooling to 30-40 ° C., the solid was recrystallized from 20 mL of refluxing ethyl acetate by cooling in a freezer for 1 hour. The slurry was suction filtered and washed with ethyl acetate cooled in a freezer to obtain 1.65 g of yellow-orange needle-like substance. mp = 158-160 ° C. Literature mp = 161-162 ° C. Gas chromatography showed the presence of the desired dialdehyde to off isomer in a 96: 4 ratio. Proton NMR and carbon NMR were consistent with the desired dialdehyde isomer.

  Yield = 66%.

Scale-up preparation of methyl tiglate using thionyl chloride in methanol:

  To a solution of tiglic acid (397.35 g, 3.97 mol) obtained by mechanically stirring in 3000 mL of methanol, neat thionyl chloride (397 mL, 5.44 mol) was added over 130 minutes without external cooling. And then treated dropwise. At this time, the temperature rose from 14 ° C. to a maximum of 50 ° C. after 80 minutes. Gas chromatography for a certain amount showed complete conversion to the ester and no tiglic acid was detected. After stirring at ambient temperature for 1 hour, the solution was distilled at atmospheric pressure through a silver-plated vacuum jacketed Vigreux column (400 mm × 20 mm). The pot temperature was 58-63 ° C. and the concentrate was collected mainly at 57-61 ° C. (630 mL over 2 hours). Gas chromatography showed significant methyl ester present in the distillate.

  The Vigreux column was replaced with a less efficient column (30 × 2 cm w / less dent) to accelerate the distillation rate. The pot temperature was 69-71 ° C. and the distillate was collected at a head temperature of 65-69 ° C. (1300 mL over 2.25 hours). Gas chromatography showed significant methyl ester present in the distillate. Atmospheric distillation continued until the pot temperature reached 87 ° C., and distillate was collected during this time at a head temperature of 69-83 ° C. (975 mL over 2 hours). Gas chromatography showed that a much larger amount of methyl ester was present in the distillate than in the initial fraction.

The yellow biphasic mixture in the pot was extracted with ether (300 & 200 mL), dried over K ₂ CO ₃ , filtered and concentrated on a rotary evaporator at 25 ° C. to give 132.6 g of an orange oil ( Yield 29.3%). Gas chromatography showed the presence of product. Proton NMR and carbon NMR were consistent with the desired product with traces of ethyl ether. Gas chromatography of the ether concentrate showed some methyl ester in the overhead.

Distillate 3: The third methanol distillate (975 mL) was concentrated on a rotary evaporator at 25 ° C. to give a two-phase mixture (100-150 mL). The mixture was extracted with ether (100 & 50 mL) and dried over K ₂ CO ₃ .

Distillate 2: A second methanol distillate (1300 mL) was concentrated on a rotary evaporator at 25 ° C. to give a two-phase mixture (30-50 mL). This mixture was extracted with ether (2 × 50 mL) and dried over K ₂ CO ₃ .

The concentrated ether extracts of Distillate 2 and Distillate 3 were combined, suction filtered, and concentrated on a rotary evaporator at 25 ° C. to give 77.3 g of a colorless oil.
Proton NMR and carbon NMR were consistent with the previously obtained spectrum of the desired methyl ester.

  Total yield = 132.6 + 77.3 = 209.9 g (46.3%)

  Alternatively, 1) methyl tiglate is commercially available from Alfa, Lancaster or Acros, and 2) the phosphonium salt can be produced experimentally according to JOC, 64, 8051-8053 (1999). it can.

Bromination of methyl tiglate:

Methyl tiglate (209.9 g, 1.84 mol), N-bromosuccinimide (327.5 g, 1.84 mol) and 70% benzoyl peroxide (3.2 g, 0.009 mol) were added to 2000 mL of carbon tetrachloride. The slurry obtained by mechanical stirring was heated to reflux (78-81 ° C.) by providing a 1 L Kugelrohr valve between the 5 L reaction flask and the reflux condenser. After 2 hours, the reflux was stopped, the mantle was removed, and the stirrer was stopped. All solids floated in the CCl ₄ solution. This suggested that the succinimide had a negligible amount of NBS. The slurry was cooled to 20 ° C. in an ice bath and suction filtered to obtain 180.7 g of an off-white solid. No washing was performed. The yellow filtrate was washed with water (1 L × 3) and dried over MgSO ₄ . Gas chromatography showed that the starting methyl tiglate and the two monobromides were present in a ratio of about 1: 2: 1, along with other minor components.

After removing MgSO ₄ by filtration, the pale yellow filtrate was concentrated on a rotary evaporator at 35 ° C. to obtain 327.1 g of a pale yellow oily substance. Proton NMR and gas chromatography suggested the following composition:

  Yield of desired product adjusted in 50% assay = 46.0%

  This oily substance is used as it is in the next step.

Scale-up reaction of methyl γ-bromotiglate with triphenylphosphine in acetonitrile with slightly higher payload:

  Under a nitrogen atmosphere, a crude mixture of methyl γ-bromotiglate (322.6 g, 85% allyl bromide, 1.42 mol) in 1300 mL of anhydrous acetonitrile placed in a 5 L four-necked flask was mechanically stirred.

  A solution of triphenylphosphine (387.0 g, 1.48 mol) dissolved in 2000 mL of ethyl acetate was added dropwise over 4 hours. During the addition, about 40% was added in the first 75 minutes, after which the temperature rose from 22 ° C up to 30 ° C. About 120% of the triphenylphosphine solution was added over 120 minutes, after which time the solution became cloudy and the remaining addition continued to precipitate solids. After the addition, the funnel was rinsed with ethyl acetate (600 mL) and further added to the reaction mixture. The creamy slurry was stirred at ambient temperature over the weekend.

  The white slurry was suction filtered, and the resulting cake was washed with ethyl acetate: acetonitrile (2: 1) (150 mL × 3). 352.55 g of the obtained white solid was dried in a vacuum dryer at 40 ° C. for 4 hours (constant weight after 2 hours) (322.55 g). mp = 187-188 ° C. (decomposition). Literature mp = 183 ° C. (decomposition). Proton NMR and carbon NMR were consistent with the previously obtained spectrum of the desired phosphonium salt. LC-MS analysis gave a molecular ion at 375 m / z, indicating the presence of one major component. The electrospray mass spectrum of its main component in positive mode was consistent with the desired phosphonium salt. Phosphorus NMR showed a single phosphorus signal at 22.0 ppm.

  Yield based on starting methyl tiglate = 100 × 322.55 / (455.32 × 1.84 × 322.6 / 327.1) = 39.0%.

Preparation of (3-carbomethoxy-2-Z-buten-1-ylidene) triphenylphosphorane:

  To a fine slurry obtained by mechanically stirring (3-carbomethoxy-2-E-butene-1-ylidene) triphenylphosphonium bromide (154.8 g, 0.34 mol) in 3400 mL of deionized water, When a solution of sodium hydroxide (13.6 g, 0.34 mol) dissolved in 500 mL of water was added dropwise over 32 minutes and treated, there was no obvious exotherm, but a bright yellow solid precipitated immediately. . After stirring for 15 minutes, the brightly colored slurry was suction filtered, washed with water (1500 mL), and dried by suction to obtain 151.7 g of a light yellow solid. The solid was dried in a vacuum dryer at 35-45 ° C. (3:50 pm) overnight.

  After drying in a vacuum dryer at 35-45 ° C. for 22.5 hours, a constant weight was obtained (107.8 g). mp = 144-160 ° C. Literature mp = 145-165 ° C. Proton NMR was similar to the previously obtained spectrum of the desired ylide, taking into account differences in the strength of the NMR magnetic field. Carbon NMR showed methyl carbon at 50.2 ppm and 11.8 ppm, with a complex aromatic region, and no clear signal for olefinic and ylide carbons.

  Yield = 84.7%.

Trial preparation of dimethyl crocetinate:

  Under nitrogen atmosphere, benzene (128 mL) in (3-carbomethoxy-2-Z-buten-1-ylidene) triphenylphosphorane (12.8 g, 34.2 mmol) and 2,7-dimethyl-2,4, A mixture obtained by adding 6-octatrienedial (2.1 g, 12.8 mmol) and stirring with a magnetic stirrer was heated to reflux for 6 hours using a timer.

The resulting slurry was cooled in an ice bath for 40 minutes, filtered with suction, washed with benzene, dried by suction and melted frozen benzene to obtain 2.1 g of a red solid. TLC analysis showed a single yellow spot. The solid was dried in a vacuum dryer at 40-45 ° C. for 70 minutes (1.85 g, 40.5% yield). Uncorrected mp = 210-213 ° C. Reference ³ mp = 214-216 ° C. [ ³ : E. Buchta & F. Andrew, Chem Ber, 93, 1349 (1960)]. Proton NMR was similar to the previously obtained spectrum of dimethyl crocetin on a 90 MHz instrument. Carbon NMR showed all 11 unique carbon signals with the exact chemical shift of the desired dimethyl ester, but with one sub-impurity signal that could be residual benzene. Electrospray mass spectra suggested fragment degradation and recombination.

TLC analysis indicated that the red filtrate contained an additional product, triphenylphosphine oxide, and an orange component with a slightly smaller R _f than the isolated solid. The red filtrate was concentrated on a rotary evaporator at 35 ° C. to obtain 13.2 g of a red solid. This solid was heated to reflux in 25 mL of methanol. The obtained slurry was cooled in an ice bath, suction filtered after 60 minutes, and washed with methanol to obtain 0.6 g of a red solid. This solid was dried in a vacuum dryer at 45 ° C. for 135 minutes (0.5 g). mp = 203-208 ° C. Proton NMR showed the presence of the desired diester with residual impurities. Carbon NMR showed only the desired product signal. TLC analysis showed streaky product spots.

  The filtrate was concentrated and stored.

Second preparation of dimethyl ester of crocetin:

  In a slurry obtained by mechanically stirring (3-carbomethoxy-2-Z-butene-1-ylidene) triphenylphosphorane (73.0 g, 195.0 mmol) in 400 mL of benzene under a nitrogen atmosphere, 2,7-Dimethyl-2,4,6-octatrienedial (11.95 g, 12.8 mmol) was added in one portion, followed by an additional 330 mL of benzene. The resulting brown slurry was heated to reflux with a timer for 6 hours, further cooled to room temperature and placed under nitrogen overnight.

  The obtained slurry was cooled to 6 to 10 ° C. in an ice bath, suction filtered, and washed with benzene (50 mL × 2) to obtain 10.05 g of a red solid. TLC analysis showed a single yellow spot. This solid was dried in a vacuum dryer at 40 ° C. (9 am) for 3.5 hours, but no weight loss was found (10.05 g, yield 38.7%). mp = 211-214 ° C. Literature mp = 214-216 ° C. Proton NMR and carbon NMR were consistent with the spectrum of the desired dimethyl ester of crocetin previously obtained.

  The red filtrate was concentrated on a rotary evaporator at 40 ° C. to obtain 84.4 g of a red solid. TLC analysis was similar to the pilot preparation. This solid was put into 165 mL of methanol and stirred with a magnetic stirrer under reflux to form a slurry. The obtained slurry was cooled in an ice bath for 2.5 hours, suction filtered, and washed with a minimum amount of methanol to obtain 10.5 g of an orange paste. TLC analysis showed a single yellow spot. The paste was dried in a vacuum oven at 45 ° C. for 190 minutes (5.6 g). mp = 201-208 ° C. NMR showed the presence of the desired diester with unknown aromatic impurities.

  This impure solid and two other similar solids from the initial run (total 6.5 g) were dissolved in 75 mL of refluxing chloroform, diluted with methanol and cooled in a refrigerator overnight.

  The slurry was suction filtered and washed with a minimum amount of methanol to obtain 6.1 g of a red crystalline solid. The solid was dried in a vacuum oven at 45 ° C. for 3 hours until constant weight (4.25 g). mp = 211-213 ° C. Proton NMR and carbon NMR showed the presence of other olefinic or aromatic impurities. The solid was dissolved in 150 mL of refluxed toluene and finally cooled in a refrigerator for 130 minutes. The slurry was suction filtered and washed with toluene to obtain 2.05 g of a red solid. This solid was dried in a vacuum dryer at 45 ° C. for 50 minutes, but no change in weight was observed (2.05 g). mp = 214-216 ° C. Proton NMR showed the presence of the desired dimethyl crocetin with some residual toluene and negligible amounts of off-isomer impurities. Carbon NMR showed the presence of the desired dimethyl crocetin, but no off-isomer impurity was detected and a few new residue signals consistent with toluene were seen. Yield = 45.5%.

Preparation of disodium salt of crocetin:

  A slurry obtained by mechanically stirring dimethyl crocetin (13.95 g, 39.1 mmol), 40 wt% aqueous sodium hydroxide solution (273 mL, 3.915 mol) and methanol (391 mL) was obtained at 74 ° C. using a timer. Heated to reflux for 12 hours.

The orange slurry was suction filtered through a Buchner funnel equipped with filter paper and a sintered glass funnel. Filtration was performed slowly ⁴ [ ⁴ : Until the filter was clogged after drying, the filtration was quicker through the sintered glass. However, the filter paper clogging disappeared after washing with water. The slurry remaining in the sintered glass funnel was added to the solid remaining in the Buchner funnel. The orange paste was washed successively with water (100 mL × 3) and methanol (50 mL × 3). The orange paste was dried at 45-50 ° C. in a vacuum dryer.

  After 21 hours, the orange mass weighed 24.25 g. The material was ground with a spatula and dried at 45-50 ° C. in a vacuum dryer.

After a total of 65.5 hours of drying, the amount of orange powder was 23.1 g. The infrared spectrum showed extra bands compared to the reported TSC IR spectrum, especially large bands at 3424 and 1444 cm ⁻¹ . Proton NMR showed no evidence of methyl ester. However, the integral values of the olefin and methyl regions have disappeared, probably due to fading problems.

  Assuming that the excess of weight was due to sodium hydroxide, the orange solid was stirred with a magnetic stirrer in 400 mL of deionized water for 35 minutes. The slurry was suction filtered, and the resulting cake was washed with deionized water (50 mL × 2) to obtain an orange paste. This material was dried in a vacuum dryer at 45-50 ° C. until constant weight. After about 7 hours, the solid was crushed, ground and further dried in a vacuum oven at 45 ° C. overnight.

  After drying at 45 ° C. for 21 hours, the amount of solid was 13.25 g. After further pulverization and drying at 45 ° C. in a vacuum dryer, the amount of solid was 13.15 g. The infrared spectrum was consistent with the reported IR spectrum. Proton NMR gave a proton NMR spectrum consistent with the disodium salt. HPLC analysis showed the presence of one major component with one possible side impurity. The main component electrospray negative ion mass spectrum was consistent with the desired disodium salt of crocetin. Carbon NMR showed all 10 unique carbon signals of disodium salt of crocetin, demonstrating molecular symmetry.

  The original filtrate of water, sodium hydroxide and methanol precipitated more solids during the water wash. The slurry was filtered with suction and washed with water to obtain an orange paste. This paste was dried in a vacuum dryer at 45 ° C. for 18.5 hours to obtain 0.65 g of an orange solid. The spectral data was consistent with the desired disodium salt of crocetin. This solid was mixed with the first crop.

  Yield = 13.15 + 0.65 = 13.8 g (94.8%).

  Elemental analysis of the first crop showed unacceptable values for the desired product, suggesting that the disodium salt of crocetin is contaminated with sodium hydroxide.

Water washing of disodium salt of crocetin:
Crocetin disodium salt (13.6 g) was placed in 150 mL of deionized water to form a slurry, and stirred with a magnetic stirrer at room temperature for 1 hour. The slurry was suction filtered with a Buchner funnel. The obtained orange paste was washed with water, and the pH of the orange filtrate was observed.

  The orange paste was sucked dry on the filter using a rubber dam. This paste was vacuum dried at 25-55 ° C. for 5.5 hours to obtain 11.2 g of a brittle orange solid. This solid was crushed, transferred to a bottle and dried in a vacuum dryer at 45 ° C. overnight.

  Amount = 11.1 g. Recovery rate = 81.6%. IR and proton NMR spectra were consistent with previously obtained IR and proton NMR spectra of the desired disodium salt of crocetin. HPLC analysis showed a single component at 420 nm and the electrospray mass spectrum of that component in negative ion mode was consistent with crocetin.

  Carbon NMR showed all 10 unique carbon signals with the exact chemical shift of the desired disodium salt of crocetin. Elemental analysis gave acceptable data on the desired product.

References:
1. Tetrahedron Letters, 27, 4983-4986 (1986).
2. F. J. et al. H. M.M. Jansen, M.M. Kwestro, D.C. Schmitt & J. Lugtenburg, Recl. Trav. Chem. Pays-Bas, 113, 552-562 (1994), and references cited therein.
3. J. et al. H. Bubbler, US Patent No. 4,107,030, Apr 21, 1992.
4). T. T. W. Gibson & P. Strassburger, J.A. Org. Chem. , 41, 791 (1976) & J. et al. M.M. Snyder & C. R. Scholfield, J.M. Am. Oil Chem. Soc. , 59, 469 (1982).

Example 6: Determination of the purity of TSC produced according to an improved synthesis method
For the TSC material synthesized according to the method of Example 5, the ratio of absorbance at 421 nm to absorbance at 254 nm was 11.1 using a UV-visible spectrophotometer.

(Example 7: Oral administration of TSC)
TSC has been shown to be absorbed into the bloodstream when administered orally (by gavage) in rats. In 2 rats, 1-2% of the given dose was found to be present in the bloodstream at 15-30 minutes after administration. The amount absorbed orally actually reached a maximum before that point.

  Those skilled in the art will readily understand that numerous changes and additions can be made to both the compounds and compositions of the present invention, and related methods, without departing from the disclosed invention. Let's go.

Claims (42)

The following structure:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
A compound having
A compound that is not transsodium crocetinate. Y ^is, Na ^+, K +, Li monovalent metal ion selected from the group consisting of ⁺ or _{^{R 4 N +, R 3 S}} + [R is, H, or _C n _{H 2n +} 1 (n is 1 to 10), It is. The compound according to claim 1, which is an organic cation selected from the group consisting of: Z is a carboxyl (COO ⁻ ) group, a sulfate group (OSO ₃ ⁻ ), or a monophosphate group (OPO ₃ ⁻ ), (OP (OH) O ₂ ⁻ ), a diphosphate group, triphosphate, or a combination thereof. The compound according to claim 1, which is selected from the group consisting of: The TCRO is a conjugated carbon-carbon double bond and a single bond containing carbon atoms, and the four single bonds around one carbon-carbon double bond are all located in the same plane. A compound of
A compound that is linear. TCRO

[Wherein X, which may be the same or different, is H, a linear or branched group having 10 or less carbon atoms and optionally containing halogen, or halogen. ]
The compound of claim 1, wherein TCRO

[Wherein X, which may be the same or different, is H, a linear or branched group having 10 or less carbon atoms and optionally containing halogen, or halogen. ]
The compound of claim 1, wherein TCRO

[Wherein X, which may be the same or different, is H, a linear or branched group having 10 or less carbon atoms and optionally containing halogen, or halogen. ]
The compound of claim 1, wherein TCRO

[Wherein X, which may be the same or different, is H, a linear or branched group having 10 or less carbon atoms and optionally containing halogen, or halogen. ]
The compound of claim 1, wherein A method for increasing the diffusibility of oxygen in a mammal, comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering to a mammal a therapeutically effective amount of a compound having:
The method wherein the compound is not transsodium crocetinate.   The method of claim 9, wherein the administration is by inhalation. A method of treating a respiratory disease,
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method for treating emphysema,
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method of treating hemorrhagic shock, comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method for treating cardiovascular disease comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method of treating atherosclerosis comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method of treating asthma,
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method of treating spinal cord injury,
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method of treating cerebral edema,
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method for treating papillomas, comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method for treating hypoxia, comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate.   A bipolar trans carotenoid salt composition in which a value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5.   A transsodium crocetinate composition in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5. A method for increasing the diffusibility of oxygen in a mammal, comprising:
Administering to a mammal a therapeutically effective amount of a bipolar trans carotenoid salt;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5. A method for treating emphysema,
Administering a therapeutically effective amount of a bipolar trans carotenoid salt to a mammal in need of treatment;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5. A method of treating hemorrhagic shock, comprising:
Administering a therapeutically effective amount of a bipolar trans carotenoid salt to a mammal in need of treatment;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5.   26. A method according to any one of claims 23 to 25, wherein the bipolar trans carotenoid salt is transsodium crocetinate. A method for increasing the diffusibility of oxygen in a mammal, comprising:
Administering a therapeutically effective amount of transsodium crocetinate to a mammal by inhalation. A method for converting an isomer mixture of olefin dialdehydes to all-trans aldehyde, comprising:
Isomerizing the isomer mixture of dialdehydes with sulfinic acid in a solvent. The sulfinic acid is represented by the formula RSO ₂ H [R is a C1-C10 linear or branched alkyl group, or an aryl group. 29. The method of claim 28, comprising:   29. The method of claim 28, wherein the solvent is selected from the group consisting of 1,4-dioxane, tetrahydrofuran or dialkyl ether, and the alkyl group is a C1-C10 linear or branched alkyl group.   29. The method of claim 28, wherein the sulfinic acid is para-toluenesulfinic acid and the solvent is 1,4-dioxane.   30. The method of claim 28, wherein the olefin dialdehyde is 2,7-dimethyl-2,4,6-octatrienedial.   29. The olefin dialdehyde is 2,7-dimethyl-2,4,6-octatrienedial, the sulfinic acid is para-toluenesulfinic acid, and the solvent is 1,4-dioxane. The method described in 1. A method of treating ischemia, comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method of treating traumatic brain injury comprising:
Following formula:
YZ-TCRO-ZY
[Where:
Y is a cation,
Z is a polar group bonded to the cation,
TCRO is a trans carotenoid skeleton. ]
Administering a therapeutically effective amount of a compound to a mammal in need of treatment,
The method wherein the compound is not transsodium crocetinate. A method of treating ischemia in a mammal, comprising:
Administering to a mammal a therapeutically effective amount of a bipolar trans carotenoid salt;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5. A method of treating traumatic brain injury comprising:
Administering a therapeutically effective amount of a bipolar trans carotenoid salt to a mammal in need of treatment;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5. A way to increase performance,
Administering to a mammal an effective amount of a bipolar trans carotenoid salt;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5. A method of treating diabetes,
Administering a therapeutically effective amount of a bipolar trans carotenoid salt to a mammal in need of treatment;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5. A method of treating Alzheimer's disease,
Administering a therapeutically effective amount of a bipolar trans carotenoid salt to a mammal in need of treatment;
A method in which the value obtained by dividing the absorbance of the maximum peak generated in the visible light wavelength region by the absorbance of the peak generated in the UV wavelength region exceeds 7.5.   41. The method of any one of claims 36-40, wherein the bipolar trans carotenoid salt is transsodium crocetinate. A method of treating or preventing ischemia resulting from mammalian surgery or reducing the amount thereof,
A method comprising administering to a mammal a therapeutically effective amount of a bipolar trans carotenoid salt before, during or after surgery.